PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

(11) International Publication Number:

WO 92/06204

C12N 15/64, 15/70

A1

(43) International Publication Date:

16 April 1992 (16.04.92)

(21) International Application Number:

PCT/US91/07149

(22) International Filing Date:

27 September 1991 (27.09.91)

(30) Priority data:

590,219

28 September 1990 (28.09.90) US

(71) Applicant: IXSYS, INC. [US/US]; 3550 General Atomics Court, Suite L103, San Diego, CA 92121 (US).

(72) Inventor: HUSE, William, D.; 471 Avenida Primavera, Del Mar, CA 92014 (US).

(74) Agents: CAMPBELL, Cathryn et al.; Pretty, Schroeder, Brueggemann & Clark, 444 South Flower Street, Suite 2000, Los Angeles, CA 90071 (US).

(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU*,TD (OAPI patent), TG (OAPI patent).

Published

With international search report.

(54) Title: SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS

(57) Abstract

A composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
ΑÜ	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinca	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	ΙT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic	SE	Sweden
CH	Switzerland		of Korea	SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	su+	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
cs	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	ŁU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

PCT/US91/07149 WO 92/06204 1

SURFACE EXPRESSION LIBRARIES OF HETEROMERIC RECEPTORS

BACKGROUND OF THE INVENTION

invention relates generally to recombinant expression of heteromeric receptors and, more particularly, expression of such receptors on the surface of filamentous bacteriophage.

Antibodies are heteromeric receptors generated by a vertebrates organism's immune system which bind to an The molecules are composed of two heavy and two 10 antigen. light chains disulfide bonded together. Antibodies have the appearance of a "Y" - shaped structure and the antigen binding portion being located at the end of both short arms The region on the heavy and light chain of the Y. 15 polypeptides which corresponds to the antigen binding portion is known as variable region. The differences between antibodies within this region are primarily responsible for the variation in binding specificities between antibody molecules. The binding specificities are a composite of the antigen interactions with both heavy and light chain polypeptides.

20

25

30

The immune system has the capability of generating an almost infinite number of different antibodies. Such a large diversity is generated primarily through recombination to form the variable regions of each chain and through differential pairing of heavy and light chains. The ability to mimic the natural immune system and generate antibodies that bind to any desired molecule is valuable because such antibodies can be used for diagnostic and therapeutic purposes.

Until recently, generation of antibodies against a

2

desired molecule was accomplished only through manipulation of natural immune responses. Methods included classical immunization techniques of animals and laboratory monoclonal antibody production. Generation of monoclonal antibodies is laborious and time consuming. It involves a series of different techniques and is only performed on animal cells. Animal cells have relatively long generation times and require extra precautions to be taken compared to procaryotic cells to ensure viability of the cultures.

10 A method for the generation of a large repertoire of diverse antibody molecules in bacteria has been described, Huse et al., Science, 246, 1275-1281 (1989), which is herein incorporated by reference. The method uses the bacteriophage lambda as the vector. The lambda vector is a long, linear double-stranded DNA molecule. Production of 15 antibodies using this vector involves the cloning of heavy and light chain populations of DNA sequences into separate vectors. The vectors are subsequently combined randomly to form a single vector which directs the coexpression of heavy and light chains to form antibody fragments. 20 disadvantage to this method is that undesired combinations of vector portions are brought together when generating the coexpression vector. Although these undesired combinations do not produce viable phage, they do however, result in a 25 significant loss of sequences from the population and, therefore, a loss in diversity of the number of different combinations which can be obtained between heavy and light chains. Additionally, the size of the lambda phage gene is large compared to the genes that encode the antibody This makes the lambda system inherently more difficult to manipulate as compared to other available vector systems.

There thus exists a need for a method to generate diverse populations of heteromeric receptors which mimics the natural immune system, which is fast and efficient and

35

PCT/US91/07149 WO 92/06204

3

results in only desired combinations without loss of diversity. The present invention satisfies these needs and provides related advantages as well.

SUMMARY OF THE INVENTION

5

25

The invention relates to a plurality of cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor, said heteromeric receptors being expressed on the surface of a cell, preferably one which 10 produces filamentous bacteriophage, such as M13. cloning systems and methods of making and screening the heteromeric receptors are also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram of the two vectors 15 used for surface expression library construction from heavy M13IX30 (Figure 1A) is the and light chain libraries. vector used to clone the heavy chain sequences (open box). The single-headed arrow represents the Lac p/o expression sequences and the double-headed arrow represents the portion of M13IX30 which is to be combined with M13IX11. The amber stop codon and relevant restriction sites are M13IX11 (Figure 1B) is the vector used to also shown. clone the light chain sequences (hatched box). Thick lines represent the pseudo-wild type (gVIII) and wild type The double-headed arrow (qVIII) gene VIII sequences. represents the portion of M13IX11 which is to be combined with M13IX30. Relevant restriction sites are also shown. Figure 1C shows the joining of vector population from heavy and light chain libraries to form the functional surface 30 expression vector M13IXHL. Figure 1D shows the generation of a surface expression library in a non-suppressor strain and the production of phage. The phage are used to infect a suppressor strain (Figure 1E) for surface expression and

20

screening of the library.

Figure 2 is the nucleotide sequence of M13IX30 (SEQ ID NO: 1).

Figure 3 is the nucleotide sequence of M13IX11 (SEQ ID 5 NO:2).

Figure 4 is the nucleotide sequence of M13IX34 (SEQ ID NO: 3) .

Figure 5 is the nucleotide sequence of M13IX13 (SEQ ID NO: 4).

Figure 6 is the nucleotide sequence of M13IX60 (SEQ ID NO: 5).

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to simple and efficient methods to generate a large repertoire of combinations of heteromeric receptors. The method is advantageous in that only proper combinations of vector portions are randomly brought together for the coexpression of different DNA sequences without loss of population size or diversity. The receptors can be expressed on the surface of cells, such as those producing filamentous bacteriophage, which can be screened in large numbers. nucleic acid sequences encoding the receptors be readily characterized because the filamentous bacteriophage produce single strand DNA for efficient sequencing and mutagenesis The heteromeric receptors so produced are useful in an unlimited number of diagnostic and therapeutic procedures.

In one embodiment, two populations of diverse heavy (Hc) and light (Lc) chain sequences are synthesized by

polymerase chain reaction (PCR). These populations are cloned into separate M13-based vector containing elements necessary for expression. The heavy chain vector contains a gene VIII (gVIII) coat protein sequence so that translation of the Hc sequences produces gVIII-Hc fusion proteins. The populations of two vectors are randomly combined such that only the vector portions containing the Hc and Lc sequences are joined into a single circular vector. The combined vector directs the coexpression of both Hc and Lc sequences for assembly of the two polypeptides and surface expression on M13. A mechanism also exists to control the expression of gVIII-Hc fusion proteins during library construction and screening.

As used herein, the term "heteromeric receptors" refers to proteins composed of two or more subunits which together exhibit binding activity toward particular molecule. It is understood that the term includes the subunit fragments so long as assembly of the polypeptides and function of the assembled complex is retained. Heteromeric subunits include, for example, antibodies and fragments thereof such as Fab and (Fab)₂ portions, T cell receptors, integrins, hormone receptors and transmitter receptors.

As used herein, the term "preselected molecule" refers
to a malecule which is chosen from a number of choices.
The molecule can be, for example, a protein or peptide, or
an organic molecule such as a drug. Benzodiazapam is a
specific example of a preselected molecule.

As used herein, the term "coexpression" refers to the expression of two or more nucleic acid sequences usually expressed as separate polypeptides. For heteromeric receptors, the coexpressed polypeptides assemble to form the heteromer. Therefore, "expression elements" as used herein, refers to sequences necessary for the

6

transcription, translation, regulation and sorting of the expressed polypeptides which make up the heteromeric receptors. The term also includes the expression of two subunit polypeptides which are linked but are able to assemble into a heteromeric receptor. A specific example of coexpression of linked polypeptides is where Hc and Lc polypeptides are expressed with a flexible peptide or polypeptide linker joining the two subunits into a single chain. The linker is flexible enough to allow association of Hc and Lc portions into a functional Fab fragment.

10

15

20

25

30

The invention provides for a composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.

encoding DNA sequences the polypeptides heteromeric receptors are obtained by methods known to one skilled in the art. Such methods include, for example, cDNA synthesis and polymerase chain reaction (PCR). need will determine which method or combinations of methods is to be used to obtain the desired populations of Expression can be performed in any compatible sequences. vector/host system. Such systems include, for example, plasmids or phagemids in procaryotes such as E. coli, yeast systems and other eucaryotic systems such as mammalian cells, but will be described herein in context with its presently preferred embodiment, i.e. expression on the of surface filamentous bacteriophage. Filamentous bacteriophage include, for example, M13, fl Additionally, the heteromeric receptors can also be expressed in soluble or secreted form depending on the need and the vector/host system employed.

PCT/US91/07149 WO 92/06204

7

Expression of heteromeric receptors such as antibodies or functional fragments thereof on the surface of M13 can be accomplished, for example, using the vector system shown in Figure 1. Construction of the vectors enabling one of ordinary skill to make them are explicitly set out in Example I. The complete nucleotide sequences are given in Figures 2 and 3 (SEQ ID NOS: 1 and 2). This system produces randomly combined populations of heavy (Hc) and light (Lc) chain antibody fragments functionally linked to 10 expression elements. The Hc polypeptide is produced as a fusion protein with the M13 coat protein encoded by gene The qVIII-Hc fusion protein therefore anchors the assembled Hc and Lc polypeptides on the surface of M13. The diversity of Hc and Lc combinations obtained by this system can be 5 x 10' or greater. Diversity of less than 5 x 10 can also be obtained and will be determined by the need and type of heteromeric receptor to be expressed.

Populations of Hc and Lc encoding sequences to be combined into a vector for coexpression are each cloned into separate vectors. For the vectors shown in Figure 1, diverse populations of sequences encoding Hc polypeptides are cloned into M13IX30 (SEQ ID NO: 1). Sequences encoding Lc polypeptides are cloned into M13IX11 (SEQ ID NO: 2). The populations are inserted between the Xho I-Spe I or Stu 25 I restriction enzyme sites in M13IX30 and between the Sac I-Xba I or Eco RV sites in M13IX11 (Figures 1A and B, respectively).

20

The populations of Hc and Lc sequences inserted into the vectors can be synthesized with appropriate restriction 30 recognition sequences flanking opposite ends encoding sequences but this is not necessary. allow annealing and ligation in-frame with expression elements of these sequences into a double-stranded vector appropriate restriction enzyme. restricted with the Alternatively, and a preferred embodiment, the Hc and Lc

inserted into sequences can be the vector without restriction of the DNA. This method of cloning is beneficial because naturally encoded restriction enzyme sites may be present within the sequences, thus, causing destruction of the sequence when treated with a restriction enzyme. For cloning without restriction, the sequences are treated briefly with a 3' to 5' exonuclease such as T4 DNA polymerase or exonuclease III. A 5' to 3' exonuclease will also accomplish the same function. The protruding 5' termini which remains should be complementary to singlestranded overhangs within the vector which remain after restriction at the cloning site and treatment with exonuclease. The exonuclease treated inserts are annealed with the restricted vector by methods known to one skilled The exonuclease method decreases background in the art. and is easier to perform.

10

15

20

25

30

35

The vector used for Hc populations, M13IX30 (Figure 1A; SEQ ID NO: 1) contains, in addition to expression elements, a sequence encoding the pseudo-wild type gVIII product downstream and in frame with the cloning sites. This gene encodes the wild type M13 gVIII amino acid sequence but has been changed at the nucleotide level to reduce homologous recombination with the wild type gVIII contained on the same vector. The wild type gVIII is present to ensure that at least some functional, non-fusion coat protein will be produced. The inclusion of a wild type gVIII therefore reduces the possibility of non-viable phage production and biological selection against certain peptide fusion proteins. Differential regulation of the two genes can also be used to control the relative ratio of the pseudo and wild type proteins.

Also contained downstream and in frame with the cloning sites is an amber stop codon. The stop codon is located between the inserted Hc sequences and the gVIII sequence and is in frame. As was the function of the wild

9

type gVIII, the amber stop codon also reduces biological selection when combining vector portions to produce functional surface expression vectors. This is accomplished by using a non-suppressor (sup 0) host strain the non-suppressor strains will expression after the Hc sequences but before the pseudo Therefore, the pseudo gVIII sequences. essentially never be expressed on the phage surface under these circumstances. Instead, only soluble Hc polypeptides 10 will be produced. Expression in a non-suppressor host strain can be advantageously utilized when one wishes to produce large populations of antibody fragments. codons other than amber, such as opal and ochre, or molecular switches, such as inducible repressor elements, 15 can also be used to unlink peptide expression from surface expression.

The vector used for Lc populations, M13IX11 (SEQ ID NO: 2), contains necessary expression elements and cloning sites for the Lc sequences, Figure 1B. As with M13IX30, upstream and in frame with the cloning sites is a leader sequence for sorting to the phage surface. Additionally, a ribosome binding site and Lac Z promoter/operator elements are also present for transcription and translation of the DNA sequences.

20

25 Both vectors contain two pairs of Mlu I-Hind III re-triction enzyme sites (Figures 1A and B) for joining together the Hc and Lc encoding sequences and their associated vector sequences. Mlu I and Hind III are noncompatible restriction sites. The two pairs symmetrically orientated about the cloning site so that 30 only the vector portions containing the sequences to be expressed are exactly combined into a single vector. two pairs of sites are oriented identically with respect to one another on both vectors and the DNA between the two sites must be homologous enough between both vectors to 35

10

allow annealing. This orientation allows cleavage of each circular vector into two portions and combination of essential components within each vector into a single circular vector where the encoded polypeptides can be 5 coexpressed (Figure 1C).

Any two pairs of restriction enzyme sites can be used so long as they are symmetrically orientated about the cloning site and identically orientated on both vectors. The sites within each pair, however, should be nonidentical or able to be made differentially recognized as a cleavage substrate. For example, the two pairs of restriction sites contained within the vectors shown in Figure 1 are Mlu I and Hind III. The sites are differentially cleavable by Mlu I and Hind III 15 respectively. One skilled in the art knows how to substitute alternative pairs of restriction enzyme sites for the Mlu I-Hind III pairs described above. instead of two Hind III and two Mlu I sites, a Hind III and Not I site can be paired with a Mlu I and a Sal I site, for example.

The combining step randomly brings together different Hc and Lc encoding sequences within the two diverse populations into a single vector (Figure 1C; M13IXHL). vector sequences donated from each independent vector, M13IX30 and M13IX11, are necessary for production of viable 25 Also, since the pseudo gVIII sequences are contained in M13IX30, coexpression of functional antibody fragments as Lc associated gVIII-Hc fusion proteins cannot be accomplished on the phage surface until the vector sequences are linked as shown in M13IXHL.

20

30

The combining step is performed by restricting each population of Hc and Lc containing vectors with Mlu I and Hind III, respectively. The 3' termini of each restricted vector population is digested with a 3' to 5' exonuclease

11

as described above for inserting sequences into the cloning sites. The vector populations are mixed, allowed to anneal and introduced into an appropriate host. A non-suppressor host (Figure 1D) is preferably used during initial construction of the library to ensure that sequences are not selected against due to expression as fusion proteins. Phage isolated from the library constructed in a non-suppressor strain can be used to infect a suppressor strain for surface expression of antibody fragments.

10 method for selecting a heteromeric receptor exhibiting binding activity toward a preselected molecule population of diverse heteromeric receptors, comprising: (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site; (b) operationally linking to second vector a second population of diverse DNA diverse population sequences encoding a of said second vector having two pairs of 20 polypeptides, restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector; (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and 25 second DNA sequences; (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences; and (e) determining the heteromeric receptors which bind to said preselected molecule. 30 invention also provides for determining the nucleic acid sequences encoding such polypeptides as well.

Surface expression of the antibody library is performed in an amber suppressor strain. As described above, the amber stop codon between the Hc sequence and the

12

gVIII sequence unlinks the two components in a non-suppressor strain. Isolating the phage produced from the non-suppressor strain and infecting a suppressor strain will link the Hc sequences to the gVIII sequence during expression (Figure 1E). Culturing the suppressor strain after infection allows the coexpression on the surface of M13 of all antibody species within the library as gVIII fusion proteins (gVIII-Fab fusion proteins). Alternatively, the DNA can be isolated from the non-suppressor strain and then introduced into a suppressor strain to accomplish the same effect.

The level of expression of qVIII-Fab fusion proteins can additionally be controlled at the transcriptional level. Both polypeptides of the gVIII-Fab fusion proteins 15 under the inducible control of Lac promoter/operator system. Other inducible promoters can work as well and are known by one skilled in the art. For high levels of surface expression, the suppressor library is cultured in an inducer of the Lac Z promoter such as isopropylthio-B-galactoside (IPTG). Inducible control is beneficial because biological selection against nonfunctional gVIII-Fab fusion proteins can be minimized by culturing the library under non-expressing conditions. Expression can then be induced only at the time of screening to ensure that the 25 entire population antibodies within the library are accurately represented on the phage surface. Also, this can be used to control the valency of the antibody on the phage surface.

The surface expression library is screened for specific Fab fragments which bind preselected molecules by standard affinity isolation procedures. Such methods include, for example, panning, affinity chromatography and solid phase blotting procedures. Panning as described by Parmley and Smith, Gene 73:305-318 (1988), which is incorporated herein by reference, is preferred because high

13

titers of phage can be screened easily, quickly and in small volumes. Furthermore, this procedure can select minor Fab fragments species within the population, which otherwise would have been undetectable, and amplified to substantially homogenous populations. The selected Fab fragments can be characterized by sequencing the nucleic acids encoding the polypeptides after amplification of the phage population.

The following examples are intended to illustrate but not limit the invention.

EXAMPLE I

Construction, Expression and Screening of Antibody Fragments on the Surface of M13

This example shows the synthesis of a 15 population of heavy (Hc) and light (Lc) chain antibody fragments and their expression on the surface of M13 as gene VIII-Fab fusion proteins. The expressed antibodies derive from the random mixing and coexpression of a Hc and Also demonstrated Lc pair. is the isolation and characterization of the expressed Fab fragments which bind benzodiazapam (BDP) and their corresponding nucleotide sequence.

<u>Isolation of mRNA and PCR Amplification of Antibody</u> Fragments

The surface expression library is constructed from mRNA isolated from a mouse that had been immunized with KLH-coupled benzodiazapam (BDP). BDP was coupled to keyhole limpet hemocyanin (KLH) using the techniques described in Antibodies: A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor, New York (1988), which is incorporated herein by reference. Briefly, 10.0 milligrams (mg) of keyhole limpet hemocyanin and 0.5 mg of BDP with a

14

glutaryl spacer arm N-hydroxysuccinimide linker appendages. Coupling was performed as in Jonda et al., <u>Science</u>, 241:1188 (1988), which is incorporated herein by reference. The KLH-BDP conjugate was removed by gel filtration chromatography through Sephadex G-25.

The KLH-BDP conjugate was prepared for injection into mice by adding 100 μ g of the conjugate to 250 μ l phosphate buffered saline (PBS). An equal volume of complete Freund's adjuvant was added and emulsified the entire solution for 5 minutes. Mice were injected with 300 μ l of the emulsion. Injections were given subcutaneously at several sites using a 21 gauge needle. immunization with BDP was given two weeks later. This injection was prepared as follows: 50 μ g of BDP was diluted in 250 μl of PBS and an equal volume of alum was mixed with the solution. The mice were intraperitoneally with 500 μl of the solution using a 23 gauge needle. One month later the mice were given a final injection of 50 μg of the conjugate diluted to 200 μl in PBS. This injection was given intravenously in the lateral tail vein using a 30 gauge needle. Five days after this final injection the mice were sacrificed and total cellular RNA was isolated from their spleens.

20

Total RNA was isolated from the spleen of a single

25 mouse immunized as described above by the method of
Chomczynski and Sacchi, Anal. Biochem., 162:156-159 (1987),
which is incorporated herein by reference. Briefly,
immediately after removing the spleen from the immunized
mouse, the tissue was homogenized in 10 ml of a denaturing
30 solution containing 4.0 M guanine isothiocyanate, 0.25 M
sodium citrate at pH 7.0, and 0.1 M 2-mercaptoethanol using
a glass homogenizer. One ml of sodium acetate at a
concentration of 2 M at pH 4.0 was mixed with the
homogenized spleen. One ml of saturated phenol was also
35 mixed with the denaturing solution containing the

WO 92/06204

15

homogenized spleen. Two ml of a chloroform:isoamyl alcohol (24:1 v/v) mixture was added to this homogenate. The homogenate was mixed vigorously for ten seconds and maintained on ice for 15 minutes. The homogenate was then transferred to thick-walled 50 mla polypropylene centrifuge tube (Fisher Scientific Company, Pittsburgh, The solution was centrifuged at 10,000 x g for 20 minutes at 4°C. The upper RNA-containing aqueous layer was transferred to a fresh 50 ml polypropylene centrifuge tube 10 and mixed with an equal volume of isopropyl alcohol. This solution was maintained at -20°C for at least one hour to precipitate the The solution containing the RNA. precipitated RNA was centrifuged at 10,000 x g for twenty The pelleted total cellular RNA was minutes at 4°C. collected and dissolved in 3 ml of the denaturing solution described above. Three mls of isopropyl alcohol was added to the resuspended total cellular RNA and vigorously mixed. This solution was maintained at -20°C for at least 1 hour The solution containing the to precipitate the RNA. precipitated RNA was centrifuged at 10,000 x g for ten The pelleted RNA was washed once with a minutes at 4°C. solution containing 75% ethanol. The pelleted F. . was dried under vacuum for 15 minutes and then resuspended in dimethyl pyrocarbonate (DEPC) treated (DEPC-H2O) H2O.

Poly A RNA for use in first strand cDNA synthesis was 25 prepared from the above isolated total RNA using a spincolumn kit (Pharmacia, Piscataway, NJ) as recommended by the manufacturer. The basic methodology has been described by Aviv and Leder, Proc. Natl. Acad. Sci., USA, 69:1408-1412 (1972), which is incorporated herein by reference. Briefly, one half of the total RNA isolated from a single immunized mouse spleen prepared as described above was resuspended in one ml of DEPC-treated dH2O and maintained at 65°C for five minutes. One ml of 2x high salt loading buffer (100 mM Tris-HCL at pH 7.5, 1 M sodium chloride, 2.0 mM disodium ethylene diamine tetraacetic acid (EDTA) at pH

8.0, and 0.2% sodium dodecyl sulfate (SDS)) was added to the resuspended RNA and the mixture was allowed to cool to room temperature. The mixture was then applied to an oligo-dT (Collaborative Research Type 2 or Type 3 Bedford, 5 MA) column that was previously prepared by washing the oligo-dT with a solution containing 0.1 M sodium hydroxide and 5 mM EDTA and then equilibrating the column with DEPC-The eluate was collected in a sterile treated dH₂O. polypropylene tube and reapplied to the same column after heating the eluate for 5 minutes at 65°C. 10 The oligo dT column was then washed with 2 ml of high salt loading buffer consisting of 50 mM Tris-HCL at pH 7.5, 500 mM sodium chloride, 1 mM EDTA at pH 8.0 and 0.1% SDS. oligo dT column was then washed with 2 ml of 1 X medium 15 salt buffer (50 mM Tris-HCL at pH 7.5, 100 mM sodium chloride, 1 mM EDTA at pH 8.0 and 0.1% SDS). The mRNA was eluted with 1 ml of buffer consisting of 10 mM Tris-HCL at pH 7.5, 1 mM EDTA at pH 8.0 and 0.05% SDS. The messenger RNA was purified by extracting this solution with phenol/chloroform followed by a single extraction with 100% chloroform, ethanol precipitated and resuspended in DEPC treated dH,0.

9

25

35

In preparation for PCR amplification, mRNA was used as a template for cDNA synthesis. In a typical 250 μ l reverse transcription reaction mixture, 5-10 μ g of spleen mRNA in water was first annealed with 500 ng (0.5 pmol) of either the 3' $V_{\rm H}$ primer (primer 12, Table I) or the 3' $V_{\rm L}$ primer (primer 9, Table II) at 65°C for 5 minutes. Subsequently, the mixture was adjusted to contain 0.8 mM dATP, 0.8 mM dCTP, 0.8 mM dGTP, 0.8 mM dTTP, 100 mM Tris-HCL (pH 8.6), 10 mM MgCl₂, 40 mM KCl, and 20 mM 2-ME. Moloney-Murine Leukemia Virus (Bethesda Research Laboratories (BRL), Gaithersburg, MD) Reverse transcriptase, 26 units, was added and the solution was incubated for 1 hour at 40°C. The resultant first strand cDNA was phenol extracted, ethanol precipitated and then used in the polymerase chain

reaction (PCR) procedures described below for amplification of heavy and light chain sequences.

Primers used for amplification of heavy chain Fd fragments for construction of the M13IX30 library is shown 5 in Table I. Amplification was performed in eight separate reactions, as described by Saiki et al., Science, 239:487-491 (1988), which is incorporated herein by reference, each reaction containing one of the 5' primers (primers 2 to 9; SEQ ID NOS: 7 through 14, respectively) and one of the 3' 10 primers (primer 12; SEQ ID NO: 17) listed in Table I. remaining 5' primers, used for amplification in a single reaction, are either a degenerate primer (primer 1; SEQ ID NO: 6) or a primer that incorporates inosine at four degenerate positions (primer 10; SEQ ID NO: 15). 15 remaining 3' primer (primer 11; SEQ ID NO: 16) was used to construct Fv fragments. The underlined portion of the 5' primers incorporates an Xho I site and that of the 3' primer an Spe I restriction site for cloning the amplified fragments into the M13IX30 vector in a predetermined 20 reading frame for expression.

TABLE I HEAVY CHAIN PRIMERS

CC G G 1) 5'- AGGT A CT CTCGAGTC GG - 3' 25 5' - AGGTCCAGCTGCTCGAGTCTGG - 3' 2) 5' - AGGTCCAGCTGCTCGAGTCAGG - 3' 3) 5' - AGGTCCAGCTTCTCGAGTCTGG - 3' 4) 5' - AGGTCCAGCTTCTCGAGTCAGG - 3' 5) 5' - AGGTCCAACTGCTCGAGTCTGG - 3' 30 6) 5' - AGGTCCAACTGCTCGAGTCAGG - 3' 7) 5' - AGGTCCAACTTCTCGAGTCTGG - 3' 8)

18

- 9) 5' AGGTCCAACTTCTCGAGTCAGG 3'
- T 10) 5' - AGGTIIAICTI<u>CTCGAG</u>TC GG - 3'
- 5 11) 5' CTATTA<u>ACTAGT</u>AACGGTAACAGT GGTGCCTTGCCCCA 3'
 - 12) 5' AGGCTT<u>ACTAGT</u>ACAATCCCTGG GCACAAT 3'

Primers used for amplification of mouse kappa light chain sequences for construction of the M13IX11 library are shown in Table II. These primers were chosen to contain restriction sites which were compatible with vector and not present in the conserved sequences of the mouse light chain Amplification was performed as described above in five separate reactions, each containing one of the 5' 15 primers (primers 3 to 7; SEO ID NOS: 20 through 24, respectively) and one of the 3' primers (primer 9; SEQ ID NO: 26) listed in Table II. The remaining 3' primer SEQ ID NO: 25) was used to construct Fv (primer 8; 20 fragments. The underlined portion of the 5' primers depicts a Sac I restriction site and that of the 3' primers an Xba I restriction site for cloning of the amplified fragments into the M13IX11 vector in a predetermined reading frame for expression.

25 <u>TABLE II</u> LIGHT CHAIN PRIMERS

- 1) 5' CCAGTTCCGAGCTCGTTGTGACTCAGGAATCT 3'
- 2) 5' CCAGTTCCGAGCTCGTGTTGACGCAGCCGCCC 3'
- 3) 5' CCAGTTCCGAGCTCGTGCTCACCCAGTCTCCA 3'
- 30 4) 5' CCAGTTCCGAGCTCCAGATGACCCAGTCTCCA 3'
 - 5) 5' CCAGATGTGAGCTCGTGATGACCCAGACTCCA 3'
 - 6) 5' CCAGATGTGAGCTCGTCATGACCCAGTCTCCA 3'
 - 7) 5' CCAGTTCCGAGCTCGTGATGACACAGTCTCCA 3'
 - 8) 5' GCAGCAT<u>TCTAGAGTTTCAGCTCCAGCTTGCC</u> 3'
- 35 9) 5' GCGCCGTCTAGAATTAACACTCATTCCTGTTGAA 3'

PCR amplification for heavy and light chain fragments was performed in a 100 μ l reaction mixture containing the above described products of the reverse transcription reaction (≈5µg of the cDNA-RNA hybrid), 300 nmol of 3' V_H primer (primer 12, Table I; SEQ ID NO: 17), and one of the 5' V, primers (primers 2-9, Table I; SEQ ID NOS: 7 through 14, respectively) for heavy chain amplification, or, 300 nmol of 3' V, primer (primer 9, Table II; SEQ ID NO: 26), and one of the 5' V_t primers (primers 3-7, Table II; SEQ ID NOS: 20 through 24, respectively) for each light chain amplification, a mixture of dNTPs at 200 mM, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 15 mM MgCl, 0.1% gelatin, and 2 units of Thermus aquaticus DNA polymerase. The reaction mixture was overlaid with mineral oil and subjected to 40 cycles of amplification cycle involved Each 15 amplification. denaturation at 92°C for 1 minute, annealing at 52°C for 2 minutes, and elongation at 72°C for 1.5 minutes. amplified samples were extracted twice with phenol/CHCl3 and once with CHCl3, ethanol-precipitated, and stored at -70°C in 10 mM Tris-HCl, pH 7.5 1 mM EDTA. The resultant 20 products were used in constructing the M13IX30 and M13IX11 libraries (see below).

Vestor Construction

Two M13-based vectors, M13IX30 (SEQ ID NO: 1) and M13IX11 (SEQ ID NO: 2), were constructed for the cloning and propagation of Hc and Lc populations of antibody fragments, respectively. The vectors were constructed to facilitate the random joining and subsequent surface expression of antibody fragment populations.

M13IX30 (SEQ ID NO: 1), or the Hc vector, was constructed to harbor diverse populations of Hc antibody fragments. M13mp19 (Pharmacia, Piscataway, NJ) was the starting vector. This vector was modified to contain, in addition to the encoded wild type M13 gene VIII: (1) a

20

pseudo-wild type gene VIII sequence with an amber stop codon between it and the restriction sites for cloning oligonucleotides; (2) Stu I restriction site for insertion of sequences by hybridization and, Spe I and Xho I restriction sites in-frame with the pseudo-wild type gene VIII for cloning Hc sequences; (3) sequences necessary for expression, such as a promoter, signal sequence and translation initiation signals; (4) two pairs of Hind III-Mlu I sites for random joining of Hc and Lc vector portions, and (5) various other mutations to remove redundant restriction sites and the amino terminal portion of Lac Z.

In the first step, an M13-based vector containing the pseudo gVIII and various other mutations was constructed, M13IX01F. The second step involved the construction of a small cloning site in a separate M13mp18 vector to yield M13IX03. This vector was then expanded to contain expression sequences and restriction sites for Hc sequences to form M13IX04B. The fourth and final step involved the incorporation of the newly constructed sequences in M13IX04B into M13IX01F to yield M13IX30.

Construction of M13IX01F first involved the generation of a pseudo wild-type gVIII sequence for surface expression of antibody fragments. The pseudo-wild type gene encodes the identical amino acid sequence as that of the wild type gene; however, the nucleotide sequence has been altered so that only 63% identity exists between this gene and the encoded wild type gene VIII. Modification of the gene VIII nucleotide sequence used for surface expression reduces the possibility of homologous recombination with the wild type gene VIII contained on the same vector. Additionally, the wild type M13 gene VIII was retained in the vector system to ensure that at least some functional, non-fusion coat protein would be produced. The inclusion of wild type gene

21

VIII facilitates the growth of phage under conditions where there is surface expression of the polypeptides and therefore reduces the possibility of non-viable phage production from the fusion genes.

The pseudo-wild type gene VIII was constructed by chemically synthesizing a series of oligonucleotides which encode both strands of the gene. The oligonucleotides are presented in Table III.

22

TABLE III

Pseudo-Wild Type Gene VIII Oligonucleotide Series

	Top Strand Oligonucleotides	Sequence (5' to 3')
5	VIII 03	GATCC TAG GCT GAA GGC
		GAT GAC CCT GCT AAG GCT
		GC
	VIII 04	A TTC AAT AGT TTA CAG
		GCA AGT GCT ACT GAG TAC
10		A
	VIII 05	TT GGC TAC GCT TGG GCT
		ATG GTA GTA GTT ATA GTT
	VIII 06	GGT GCT ACC ATA GGG ATT
		AAA TTA TTC AAA AAG TT
15	VIII 07	T ACG AGC AAG GCT TCT
		TA
	Bottom Strand Oligonucleotides	
1149	VIII 08	AGC TTA AGA AGC CTT GCT
20		CGT AAA CTT TTT GAA TAA
		TTT
	VIII 09	TTT AAT CCC TAT GGT AGC ACC
	VIII 09	
	VIII 09	AAT CCC TAT GGT AGC ACC
25		AAT CCC TAT GGT AGC ACC AAC TAT AAC TAC TAC CAT
25		AAT CCC TAT GGT AGC ACC AAC TAT AAC TAC TAC CAT AGC CCA AGC GTA GCC AAT
25	VIII 10	AAT CCC TAT GGT AGC ACC AAC TAT AAC TAC TAC CAT AGC CCA AGC GTA GCC AAT GTA CTC AGT AGC ACT TG

Except for the terminal oligonucleotides VIII 03 (SEQ 30 ID NO: 27) and VIII 08 (SEQ ID NO: 32), the above oligonucleotides (oligonucleotides VIII 04-07 (SEQ ID NOS: 28 through 31, respectively) and VIII 09-12 (SEQ ID NOS: 33

10

15

through 36, respectively)) were mixed at 200 ng each in 10 μ l final volume, phosphorylated with T4 polynucleotide Kinase (Pharmacia) and 1 mM ATP at 37°C for 1 hour, heated to 70°C for 5 minutes, and annealed into double-stranded form by heating to 65°C for 3 minutes, followed by cooling to room temperature over a period of 30 minutes. reactions were treated with 1.0 U of T4 DNA ligase (BRL) and 1 mM ATP at room temperature for 1 hour, followed by heating to 70°C for 5 minutes. Terminal oligonucleotides were then annealed to the ligated oligonucleotides. annealed and ligated oligonucleotides yielded a doublestranded DNA flanked by a Bam HI site at its 5' end and by a Hind III site at its 3' end. A translational stop codon (amber) immediately follows the Bam HI site. The gene VIII sequence begins with the codon GAA (Glu) two codons 3' to the stop codon. The double-stranded insert was cloned in frame with the Eco RI and Sac I sites within the M13 To do so, M13mp19 was digested with Bam HI polylinker. (New England Biolabs, Beverley, MA) and Hind III (New England Biolabs) and combined at a molar ratio of 1:10 with the double-stranded insert. The ligations were performed at room temperature overnight in 1% ligase buffer (50 mM Tris-HCl, pH 7.8, 10 mM MgCl, 20 mM DTT, 1 mM ATP, 50 μ g/ml BSA) containing 1.0 U of T4 DNA ligase (New England Biolabs). The ligation mixture was transformed into a host and screened for positive clones using standard procedures in the art.

Several mutations were generated within the construct to yield functional M13IXO1F. The mutations were generated using the method of Kunkel et al., Meth. Enzymol. 154:367-382 (1987), which is incorporated herein by reference, for site-directed mutagenesis. The reagents, strains and protocols were obtained from a Bio Rad Mutagenesis kit (Bio Rad, Richmond, CA) and mutagenesis was performed as recommended by the manufacturer.

35

Two Fok I sites were removed from the vector as well as the Hind III site at the end of the pseudo gene VIII sequence using the mutant oligonucleotides CATTTTTGCAGATGGCTTAGA-3' 51-(SEO ID NO: 37) TAGCATTAACGTCCAATA-3' (SEQ ID NO: 38). New Hind III and Mlu I sites were also introduced at position 3919 and 3951 The oligonucleotides used M13IX01F. for mutagenesis had the sequences ATATATTTAGTAAGCTTCATCTTCT-3' (SEQ ID NO: 39) and 5'-GACAAAGAACGCGTGAAAACTTT-3' (SEQ ID NO: 40), respectively. 10 The amino terminal portion of Lac Z was deleted by oligonucleotide-directed mutagenesis using the oligonucleotide 5'-GCGGGCCTCTTCGCTATTGCTTAAGAAGCCTTGCT-3' (SEQ ID NO: 41). In constructing the above mutations, all changes made in a M13 coding region were performed such 15 that the amino acid sequence remained unaltered. resultant vector, M13IX01F, was used in the final step to construct M13IX30 (see below).

In the second step, M13mp18 was mutated to remove the 5' end of Lac Z up to the Lac i binding site and including 20 Lac \mathbf{z} ribosome binding site and start Additionally, the polylinker was removed and a Mlu I site was introduced in the coding region of Lac Z. oligonucleotide was used for these mutagenesis and had the 25 sequence 5'-AAACGACGGCCAGTGCCAAGTGACGCGTGTGAAATTGTTATCC-3' (SEQ ID NO: 42). Restriction enzyme sites for Hind III and Eco RI were introduced downstream of the Mlu I site using the oligonucleotide 5'-GGCGAAAGGGAATTCTGCAAGGCGATTAAGCTTGGG TAACGCC-3' (SEQ ID NO. 43). These modifications of M13mp18 yielded the precursor vector M13IX03. 30

expression sequences and cloning sites were introduced into M13IX03 by chemically synthesizing a series of oligonucleotides which encode both strands of the desired sequence. The oligonucleotides are presented in Table IV.

25

TABLE IV
M13IX30 Oligonucleotide Series

	Top Strand <u>Oligonucleotides</u>	Sequence (5' to 3')
5	084	GGCGTTACCCAAGCTTTGTACATGGAGAAAATAAAG
	027	TGAAACAAAGCACTATTGCACTGGCACTCTTACCGT TACCGT
	028	TACTGTTTACCCCTGTGACAAAAGCCGCCCAGGTCC AGCTGC
10	029	TCGAGTCAGGCCTATTGTGCCCAGGGATTGTACTAG TGGATCCG
	Detter	
	Bottom <u>Oligonucleotides</u>	Sequence (5' to 3')
		Sequence (5' to 3') TGGCGAAAGGGAATTCGGATCCACTAGTACAATCCCTG
15	Oligonucleotides	
15	Oligonucleotides 085	TGGCGAAAGGGAATTCGGATCCACTAGTACAATCCCTG GGCACAATAGGCCTGACTCGAGCAGCTGGACCAGGGCG
15	Oligonucleotides 085 031	TGGCGAAAGGGAATTCGGATCCACTAGTACAATCCCTG GGCACAATAGGCCTGACTCGAGCAGCTGGACCAGGGCG GCTT TTGTCACAGGGGTAAACAGTAACGGTAACGGTAAGTGT

The above oligonucleotides of Table IV, except for the terminal oligonucleotides 084 (SEQ ID NO: 44) and 085 (SEQ ID NO: 48), were mixed, phosphorylated, annealed and ligated to form a double-stranded insert as described in 25 Example I. However, instead of cloning directly into the intermediate vector the insert was first amplified by PCR. The terminal oligonucleotides were used as primers for PCR. Oligonucleotide 084 (SEQ ID NO: 44) contains a Hind III nucleotides internal to its 5' end 30 oligonucleotide 085 (SEQ ID NO: 48) has an Eco RI site at Following amplification, the products were its 5' end. restricted with Hind III and Eco RI and ligated, as described in Example I, into the polylinker of M13mp18 digested with the same two enzymes. The resultant double

stranded insert contained a ribosome binding site, a translation initiation codon followed by a leader sequence and three restriction enzyme sites for cloning random oligonucleotides (Xho I, Stu I, Spe I). The intermediate vector was named M13IX04.

During cloning of the double-stranded insert, it was found that one of the GCC codons in oligonucleotides 028 and its complement in 031 was deleted. Since this deletion did not affect function, the final construct is missing one of the two GCC codons. Additionally, oligonucleotide 032 (SEQ ID NO: 50) contained a GTG codon where a GAG codon was needed. Mutagenesis performed was using the oligonucleotide 5'-TAACGGTAAGAGTGCCAGTGC-3' (SEQ ID NO: 52) to convert the codon to the desired sequence. The resultant vector is named M13IX04B.

15

20

The third step in constructing M13IX30 inserting the expression and cloning sequences M13IX04B upstream of the pseudo wild-type gVIII M13IXO1F. This was accomplished by digesting M13IX04B with Dra III and Bam HI and gel isolating the 700 base pair insert containing the sequences of interest. M13IX01F was likewise digested with Dra III and Bam HI. The insert was combined with the double digested vector at a molar ratio of 1:1 and ligated as described in Example I. The sequence of the final construct M13IX30, is shown in Figure 2 (SEQ ID NO: 1). Figure 1A also shows M13IX30 where each of the elements necessary for surface expression of Hc fragments is marked. It should be noted during modification of the vectors, certain sequences differed from the published sequence of M13mp18. The new sequences are incorporated into the sequences recorded herein.

M13IX11 (SEQ ID NO: 2), or the Lc vector, was constructed to harbor diverse populations of Lc antibody fragments. This vector was also constructed from M13mp19

27

and contains: (1) sequences necessary for expression, such as a promoter, signal sequence and translation initiation signals; (2) Eco RV restriction site for insertion of sequences by hybridization and Sac I and Xba I restriction sites for cloning of Lc sequences; (3) two pairs of Hind III-Mlu I sites for random joining of Hc and Lc vector portions, and (4) various other mutation to remove redundant restriction sites.

The expression, translation initiation signals, cloning sites, and one of the Mlu I sites were constructed by annealing of overlapping oligonucleotides as described above to produce a double-stranded insert containing a 5' Eco RI site and a 3' Hind III site. The overlapping oligonucleotides are shown in Table V and were ligated as a cuble-stranded insert between the Eco RI and Hind III sites of M13mp18 as described for the expression sequences inserted into M13IX03. The ribosome binding site (AGGAGAC) is located in oligonucleotide 015 and the translation initiation codon (ATG) is the first three nucleotides of oligonucleotide 016 (SEQ ID NO: 55).

Oligonucleotide Series for Construction of
Translation Signals in M13IX11

	Oligonucleotide	Sequence (5' to 3')
5	082	CACC TTCATG AATTC GGC AAG GAGACA GTCAT
	015	AATT C GCC AAG GAG ACA GTC AT
	016	AATG AAA TAC CTA TTG CCT ACG
		GCA GCC GCT GGA TTG TT
10	017	ATTA CTC GCT GCC CAA CCA GCC
	•	ATG GCC GAG CTC GTG AT
	018	GACC CAG ACT CCA GATATC CAA
		CAG GAA TGA GTG TTA AT
	019	TCT AGA ACG CGT C
15	083	TTCAGGTTGAAGC TTA CGC GTT
	·	CTA GAA TTA ACA CTC ATT
		CCTGT
	021	TG GAT ATC TGG AGT CTG GGT
	i i	CAT CAC GAG CTC GGC CAT G
20	022	GC TGG TTG GGC AGC GAG TAA
		TAA CAA TCC AGC GGC TGC C
	023	GT AGG CAA TAG GTA TTT CAT
		TAT GAC TGT CCT TGG CG

Oligonucleotide 017 (SEQ ID NO: 56) contained a Sac I restriction site 67 nucleotides downstream from the ATG codon. The naturally occurring Eco RI site was removed and new Eco RI and Hind III sites were introduced downstream from the Sac I. Oligonucleotides 5'-TGACTGTCTCCTTGGCGTGTGAAATTGTTA-3' (SEQ ID NO: 63) and 5'-TAACACTCATTCCGGATGGAATTCTGGAGTCTGGGT-3' (SEQ ID NO: 64) were used to generate each of the mutations, respectively. The Lac Z ribosome binding site was removed when the

15

20

original Eco RI site in M13mp19 was mutated. Additionally, when the new Eco RI and Hind III sites were generated, a spontaneous 100 bp deletion was found just 3' to these sites. Since the deletion does not affect the function, it was retained in the final vector.

In addition to the above mutations, a variety of other modifications were made to incorporate or remove certain sequences. The Hind III site used to ligate the double-stranded insert was removed with the oligonucleotide 5'-GCCAGTGCCAAGTGACGCGTTCTA-3' (SEQ ID NO: 65). Second Hind III and Mlu I sites were introduced at positions 3922 and 3952, respectively, using the oligonucleotides 5'-ATATATTTTAGTAAGCTTCATCTTCT-3' (SEQ ID NO: 66) for the Hind III mutagenesis and 5'-GACAAAGAACGCGTGAAAACTTT-3' (SEQ ID NO: 67) for the Mlu I mutagenesis. Again, mutations within the coding region did not alter the amino acid sequence.

The sequence of the resultant vector, M13IX11, is shown in Figure 3 (SEQ ID NO: 2). Figure 1B also shows M13IX11 where each of the elements necessary for producing a surface expression library between Lc fragments is marked.

Library Construction

Each population of Hc and Lc sequences synthesized by PCR above are separately cloned into M13IX30 and M13IX11, respectively, to create Hc and Lc libraries.

The Hc and Lc products (5 μ g) are mixed, ethanol precipitated and resuspended in 20 μ l of NaOAc buffer (33 mM Tris acetate, pH 7.9, 10 mM Mg-acetate, 66 mM K-acetate, 0.5 mM DTT). Five units of T4 DNA polymerase is added and the reactions incubated at 30°C for 5 minutes to remove 3' termini by exonuclease digestion. Reactions are stopped by heating at 70°C for 5 minutes. M13IX30 is digested with

30

Stu I and M13IX11 is digested with Eco RV. Both vectors are treated with T4 DNA polymerase as described above and combined with the appropriate PCR products at a 1:1 molar ratio at 10 ng/ μ l to anneal in the above buffer at room temperature overnight. DNA from each annealing is electroporated into MK30-3 (Boehringer, Indianapolis, IN), as described below, to generate the Hc and Lc libraries.

E. coli MK30-3 is electroporated as described by Smith et al., Focus 12:38-40 (1990) which is incorporated herein by reference. The cells are prepared by inoculating a fresh colony of MK30-3 into 5 mls of SOB without magnesium (20 g bacto-tryptone, 5 g bacto-yeast extract, 0.584 g NaCl, 0.186 g KCl, dH₂O to 1,000 mls) and grown with vigorous aeration overnight at 37°C. SOB without magnesium (500 ml) is inoculated at 1:1000 with the overnight culture and grown with vigorous aeration at 37°C until the OD_{550} is (about 2 to 3 h). The cells are harvested by centrifugation at 5,000 rpm (2,600 x g) in a GS3 rotor (Sorvall, Newtown, CT) at 4°C for 10 minutes, resuspended in 500 ml of ice-cold 10% (v/v) sterile glycerol, 20 centrifuged and resuspended a second time in the same After a third centrifugation, the cells are resuspended in 10% sterile glycerol at a final volume of about 2 ml, such that the OD₅₅₀ of the suspension was 200 to 300. Usually, resuspension is achieved in the 10% glycerol that remained in the bottle after pouring off the supernate. Cells are frozen in 40 μ l aliquots in microcentrifuge tubes using a dry ice-ethanol bath and stored frozen at -70°C.

Frozen cells are electroporated by thawing slowly on ice before use and mixing with about 10 pg to 500 ng of vector per 40 μ l of cell suspension. A 40 μ l aliquot is placed in an 0.1 cm electroporation chamber (Bio-Rad, Richmond, CA) and pulsed once at 0°C using 4 k Ω parallel resistor 25 μ F, 1.88 KV, which gives a pulse length (τ) of

 $^{-4}$ ms. A 10 μ l aliquot of the pulsed cells are diluted into 1 ml SOC (98 mls SOB plus 1 ml of 2 M MgCl₂ and 1 ml of 2 M glucose) in a 12- x 75-mm culture tube, and the culture is shaken at 37°C for 1 hour prior to culturing in selective media, (see below).

Each of the libraries are cultured using methods known Such methods can be found in to one skilled in the art. Sanbrook et al., Molecular Cloning: A Laboratory Manuel, Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989, and in Ausubel et al., Current Protocols in Molecular 10 Biology, John Wiley and Sons, New York, 1989, both of which are incorporated herein by reference. Briefly, the above 1 ml library cultures are grown up by diluting 50-fold into 2XYT media (16 g tryptone, 10 g yeast extract, 5 g NaCl) and culturing at 37°C for 5-8 hours. The bacteria are 15 pelleted by centrifugation at 10,000 x g. The supernatant containing phage is transferred to a sterile tube and stored at 4°C.

Double strand vector DNA containing Hc and Lc antibody fragments are isolated from the cell pellet of each 20 library. Briefly, the pellet is washed in TE (10 mM Tris, pH 8.0, 1 mM EDTA) and recollected by centrifugation at 7,000 rpm for 5' in a Sorval centrifuge (Newtown, CT). Pellets are resuspended in 6 mls of 10% Sucrose, 50 mM 3.0 ml of 10 mg/ μ l lysozyne is added and Tris, pH 8.0. 25 incubated on ice for 20 minutes. 12 mls of 0.2 M NaOH, 1% is added followed by 10 minutes on ice. The suspensions are then incubated on ice for 20 minutes after addition of 7.5 mls of 3 M NaOAc, pH 4.6. The samples are centrifuged at 15,000 rpm for 15 minutes at 4°C, RNased and extracted with phenol/chloroform, followed by ethanol precipitation. The pellets are resuspended, weighed and an equal weight of CsCl2 is dissolved into each tube until a EtBr is added to 600 density of 1.60 g/ml is achieved. isolated by μg/ml and the double-stranded DNA is 35

equilibrium centrifugation in a TV-1665 rotor (Sorval) at 50,000 rpm for 6 hours. These DNAs from each right and left half sublibrary are used to generate forty libraries in which the right and left halves of the randomized oligonucleotides have been randomly joined together.

The surface expression library is formed by the random joining of the Hc containing portion of M13IX30 with the Lc containing portion of M13IX11. The DNAs isolated from each library was digested separately with an excess amount of restriction enzyme. The Lc population (5 μ g) is digested The Hc (5 μ g) population is digested with with Hind III. The reactions are stopped by phenol/chloroform Mlu I. extraction followed by ethanol precipitation. The pellets are washed in 70% ethanol and resuspended in 20 μl of NaOAc Five units of T4 DNA polymerase (Pharmacia) is 15 buffer. added and the reactions incubated at 30°C for 5 minutes. Reactions are stopped by heating at 70°C for 5 minutes. The Hc and Lc DNAs are mixed to a final concentration of 10 ng each vector/ μ l and allowed to anneal at room temperature 20 overnight. The mixture is electroporated into MK30-3 cells as described above.

Screening of Surface Expression Libraries

25

30

Purified phage are prepared from 50 ml liquid cultures of XL1 BlueTM cells (Stratagene, La Jolla, CA) which had been infected at a m.o.i. of 10 from the phage stocks stored at 4°C. The cultures are induced with 2 mM IPTG. Supernatants are cleared by two centrifugations, and the phage are precipitated by adding 1/7.5 volumes of PEG solution (25% PEG-8000, 2.5 M NaCl), followed by incubation at 4°C overnight. The precipitate is recovered by centrifugation for 90 minutes at 10,000 x g. Phage pellets are resuspended in 25 ml of 0.01 M Tris-HCl, pH 7.6, 1.0 mM EDTA, and 0.1% Sarkosyl and then shaken slowly at room temperature for 30 minutes. The solutions are adjusted to

0.5 M NaCl and to a final concentration of 5% polyethylene glycol. After 2 hours at 4°C, the precipitates containing the phage are recovered by centrifugation for 1 hour at 15,000 X g. The precipitates are resuspended in 10 ml of NET buffer (0.1 M NaCl, 1.0 mM EDTA, and 0.01 M Tris-HCl, pH 7.6), mixed well, and the phage repelleted by centrifugation at 170,000 X g for 3 hours. The phage pellets are resuspended overnight in 2 ml of NET buffer and subjected to cesium chloride centrifugation for 18 hours at 110,000 X g (3.86 g of cesium chloride in 10 ml of buffer). Phage bands are collected, diluted 7-hold with NET buffer, recentrifuged at 170,000 X g for 3 hours, resuspended, and stored at 4°C in 0.3 ml of NET buffer containing 0.1 mM sodium azide.

The BDP used for panning on streptavidin coated dishes 15 is first biotinylated and then absorbed against UVinactivated blocking phage (see below). The biotinylating reagents are dissolved in dimethylformamide at a ratio of solid NHS-SS-Biotin (sulfosuccinimidyl 2.4 mg (biotinamido) ethyl-1,3'-dithiopropionate; Pierce, Rockford, 20 IL) to 1 ml solvent and used as recommended by the Small-scale reactions are accomplished by manufacturer. mixing 1 μ l dissolved reagent with 43 μ l of 1 mg/ml BDP diluted in sterile bicarbonate buffer (0.1 M NaHCOz, pH 8.6). After 2 hours at 25°C, residual biotinylating 25 reagent is reacted with 500 μ l 1 M ethanolamine (pH adjusted to 9 with HCl) for an additional 2 hours. The entire sample is diluted with 1 ml TBS containing 1 mg/ml BSA, concentrated to about 50 μ l on a Centricon 30 ultrafilter (Amicon), and washed on the same filter three times with 2 ml TBS and once with 1 ml TBS containing 0.02% NaN3 and 7 x 10 12 UV-inactivated blocking phage (see below); the final retentate (60-80 μ l) is stored at 4 °C. biotinylated with the NHS-SS-Biotin reagent is linked to biotin via a disulfide-containing chain.

34

UV-irradiated M13 phage are used for blocking any biotinylated BDP which fortuitously binds filamentous phage in general. M13mp8 (Messing and Vieira, Gene 19: 262-276 (1982), which is incorporated herein by reference) is chosen because it carries two amber mutations, which ensure that the few phage surviving irradiation will not grow in the sup O strains used to titer the surface expression library. A 5 ml sample containing 5 x 10¹³ M13mp8 phage, purified as described above, is placed in a small petri plate and irradiated with a germicidal lamp at a distance of two feet for 7 minutes (flux 150 μW/cm²). NaN₃ is added to 0.02% and phage particles concentrated to 10¹⁴ particles/ml on a Centricon 30-kDa ultrafilter (Amicon).

For panning, polystyrene petri plates (60 x 15 mm) are incubated with 1 ml of 1 mg/ml of streptavidin (BRL) in 0.1 M NaHCO₃ pH 8.6-0.02% NaN₃ in a small, air-tight plastic box overnight in a cold room. The next day streptavidin is removed and replaced with at least 10 ml blocking solution (29 mg/ml of BSA; 3 μg/ml of streptavidin; 0.1 M NaHCO₃ pH 8.6-0.02% NaN₃) and incubated at least 1 hour at room temperature. The blocking solution is removed and plates are washed rapidly three times with Tris buffered saline containing 0.5% Tween 20 (TBS-0.5% Tween 20).

Selection of phage expressing antibody fragments which bind BDP is performed with 5 μl (2.7 μg BDP) of blocked biotinylated BDP reacted with a 50 μl portion of the library. Each mixture is incubated overnight at 4°C, diluted with 1 ml TBS-0.5% Tween 20, and transferred to a streptavidin-coated petri plate prepared as described above. After rocking 10 minutes at room temperature, unbound phage are removed and plates washed ten times with TBS-0.5% Tween 20 over a period of 30-90 minutes. Bound phage are eluted from plates with 800 μl sterile elution buffer (1 mg/ml BSA, 0.1 M HCl, pH adjusted to 2.2 with glycerol) for 15 minutes and eluates neutralized with 48 μl

2 M Tris (pH unadjusted). A 20 μ l portion of each eluate is titered on MK30-3 concentrated cells with dilutions of input phage.

A second round of panning is performed by treating 750 μ l of first eluate from the library with 5 mM DTT for 10 minutes to break disulfide bonds linking biotin groups to residual biotinylated binding proteins. The treated eluate is concentrated on a Centricon 30 ultrafilter (Amicon), washed three times with TBS-0.5% Tween 20, and concentrated to a final volume of about 50 μ l. Final retentate is transferred to a tube containing 5.0 μ l (2.7 μ g BDP) blocked biotinylated BDP and incubated overnight. solution is diluted with 1 ml TBS-0.5% Tween 20, panned, and eluted as described above on fresh streptavidin-coated The entire second eluate (800 μ 1) petri plates. neutralized with 48 μ l 2 M Tris, and 20 μ l is titered simultaneously with the first eluate and dilutions of the input phage. If necessary, further rounds of panning can be performed to obtain homogeneous populations of phage. Additionally, phage can be plaque purified if reagents are available for detection.

Template Preparation and Sequencing

Templates are prepared for sequencing by inoculating a 1 ml culture of 2XYT containing a 1:100 dilution of an overnight culture of XL1 with an individual plaque from the purified population. The plaques are picked using a sterile toothpick. The culture is incubated at 37°C for 5-6 hours with shaking and then transferred to a 1.5 ml microfuge tube. 200 μ l of PEG solution is added, followed by vortexing and placed on ice for 10 minutes. The phage precipitate is recovered by centrifugation in a microfuge at 12,000 x g for 5 minutes. The supernatant is discarded and the pellet is resuspended in 230 μ l of TE (10 mM TrisHCl, pH 7.5, 1 mM EDTA) by gently pipeting with a yellow

20

25

pipet tip. Phenol (200 μ l) is added, followed by a brief vortex and microfuged to separate the phases. The aqueous phase is transferred to a separate tube and extracted with 200 μ l of phenol/chloroform (1:1) as described above for the phenol extraction. A 0.1 volume of 3 M NaOAc is added, followed by addition of 2.5 volumes of ethanol and precipated at -20°C for 20 minutes. The precipated templates are recovered by centrifugation in a microfuge at 12,000 x g for 8 minutes. The pellet is washed in 70% ethanol, dried and resuspended in 25 μ l TE. Sequencing was performed using a Sequenase sequencing kit following the protocol supplied by the manufacturer (U.S. Biochemical, Cleveland, OH).

EXAMPLE II

Cloning of Heavy and Light Chain Sequences Without Restriction Enzyme Digestion

This example shows the simultaneous incorporation of antibody heavy and light chain fragment encoding sequences into a M13IXHL-type vector with the use of restriction endonucleases.

For the simultaneous incorporation of heavy and light chain encoding sequences into a single coexpression vector, a M13IXHL vector was produced that contained heavy and light chain encoding sequences for a mouse monoclonal antibody (DAN-18H4; Biosite, San Diego, CA). The inserted antibody fragment sequences are used as complementary sequences for the hybridization and incorporation of Hc and Lc sequences by site-directed mutagenesis. The genes encoding the heavy and light chain polypeptides were inserted into M13IX30 (SEQ ID NO: 1) and M13IX11 (SEQ ID NO: 2), respectively, and combined into a single surface expression vector as described in Example I. The resultant M13IXHL-type vector is termed M13IX50.

25

The combinations were performed under conditions that facilitate the formation of one Hc and one Lc vector half into a single circularized vector. Briefly, the overhangs generated between the pairs of restriction sites after restriction with Mlu I or Hind III and exonuclease digestion are unequal (i.e., 64 nucleotides compared to 32 nucleotides). These unequal lengths result in differential hybridization temperatures for specific annealing of the complementary ends from each vector. The specific hybridization of each end of each vector half was accomplished by first annealing at 65°C in a small volume (about 100 $\mu g/\mu l$) to form a dimer of one Hc vector half and one Lc vector half. The dimers were circularized by diluting the mixture (to about 20 μ g/ μ l) and lowering the temperature to about 25-37°C to allow annealing. T4 ligase was present to covalently close the circular vectors.

M13IX50 was modified such that it did not produce a functional polypeptide for the DAN monoclonal antibody. do this, about eight amino acids were changed within the variable region of each chain by mutagenesis. The Lc variable region was mutagenized using the oligonucleotide 5 '-CTGAACCTGTCTGGGACCACAGTTGATGCTATAGGATCAGATCTAGAATTCATT TAGAGACTGGCCTGGCTTCTGC-3' (SEQ ID NO: 68). The Hc sequence oligonucleotide mutagenized with the T C G A C C G T T G G T A G G A A T A A T G C A A T T A A T G GAGTAGCTCTAAATTCAGAATTCATCTACACCCAGTGCATCCAGTAGCT-3' (SEQ ID NO: 69). An additional mutation was also introduced into M13IX50 to yield the final form of the vector. During intermediate to M13IX50 (M13IX04 construction of an described in Example I), a six nucleotide sequence was 30 duplicated in oligonucleotide 027 and its complement 032. This sequence, 5'TTACCG-3' was deleted by mutagenesis using the oligonucleotide 5'-GGTAAACAGTAACGGTAAGAGTGCCAG-3' (SEQ ID NO: 70). The resultant vector was designated M13IX53.

WO 92/06204 PCT/US91/07149

38

contains all the functional elements of the previously described M13IXHL vector except that it does not express functional antibody heteromers. The single-stranded vector can be hybridized to populations of single-stranded Hc and Lc encoding sequences for their incorporation into the vector by mutagenesis. Populations of single-stranded Hc and Lc encoding sequences can be produced by one skilled in the art from the PCR products described in Example I or by other methods known to one skilled in the art using the primers and teachings described therein. The resultant vectors with Hc and Lc encoding sequences randomly incorporated are propagated and screened for desired binding specificities as described in Example I.

Other vectors similar to M13IX53 and the vectors it's derived from, M13IX11 and M13IX30, have also been produced for the incorporation of Hc and Lc encoding sequences without restriction. In contrast to M13IX53, these vectors contain human antibody sequences for the efficient hybridization and incorporation of populations of human Hc and Lc sequences. These vectors are briefly described below. The starting vectors were either the Hc vector (M13IX30) or the Lc vector (M13IX11) previously described.

20

25

30

M13IX32 was generated from M13IX30 by removing the six nucleotide redundant sequence 5'-TTACCG-3' described above and mutation of the leader sequence to increase secretion of the product. The oligonucleotide used to remove the redundant sequence is the same as that given above. The mutation in the leader sequence was generated using the oligonucleotide 5'GGGCTTTTGCCACAGGGGT-3'. This mutagenesis resulted in the A residue at position 6353 of M13IX30 being changed to a G residue.

A decapeptide tag for affinity purification of antibody fragments was incorporated in the proper reading frame at the carboxy-terminal end of the Hc expression site

in M13IX32. The oligonucleotide used for this mutagenesis was 5'-CGCCTT CAGCCTAAGAAGCGTAGTCCGGAACGTCGTACGGGTAGGATCCA CTAG-3' (SEQ ID NO: 71). The resultant vector was designated M13IX33. Modifications to this or other vectors are envisioned which include various features known to one skilled in the art. For example, a peptidase cleavage site can be incorporated following the decapeptide tag which allows the antibody to be cleaved from the gene VIII portion of the fusion protein.

10 M13IX34 (SEQ ID NO: 3) was created from M13IX33 by cloning in the gene encoding a human IgG1 heavy chain. The reading frame of the variable region was changed and a stop codon was introduced to ensure that a functional polypeptide would not be produced. The oligonucleotide used for the mutagenesis of the variable region was 5'-CACCGGTTCGGGGAATTAGTCTTGACCAGGCAGCCCAGGGC-3' (SEQ ID NO: 72). The complete nucleotide sequence of this vector is shown in Figure 4 (SEQ ID NO: 3).

Several vectors of the M13IX11 series were also generated to contain similar modifications that 20 described for the vectors M13IX53 and M13IX34. The promoter region in M13IX11 was mutated to conform to the 35 to generate M13IX12. sequence oligonucleotide used for this mutagenesis was 5'-ATTCCACAC ATTATACGAGCCGGAAGCATAAAGTGTCAAGCCTGGGGTGCC-3' (SEQ ID NO: 73). A human kappa light chain sequence was cloned into M13IX12 and the variable region subsequently deleted to generate M13IX13 (SEQ ID NO: 4). The complete nucleotide sequence of this vector is shown in Figure 5 (SEQ ID NO: A similar vector, designated M13IX14, was also generated in which the human lambda light chain was inserted into M13IX12 followed by deletion of the variable The oligonucleotides used for the variable region 5'-CTG deletion of M13IX13 and M13IX14 were 35 CTCATCAGATGGCGGGAAGAGCTCGGCCATGGCTGGTTG-3' (SEQ ID NO: 74)

and 5'-GAACAGAGT GACCGAGGGGGGGGGCGAGCTCGGCCATGGCTGGTTG-3' (SEQ ID NO: 75), respectively.

The Hc and Lc vectors or modified forms thereof can be combined using the methods described in Example I to produce a single vector similar to M13IX53 that allows the efficient incorporation of human Hc and Lc encoding sequences by mutagenesis. An example of such a vector is the combination of M13IX13 with M13IX34. The complete nucleotide sequence of this vector, M13IX60, is shown in Figure 6 (SEQ ID NO: 5).

10

Additional modifications to any of the previously described vectors can also be performed to generate vectors allow the efficient incorporation and surface expression of Hc and Lc sequences. For example, alleviate the use of uracil selection against wild-type template during mutagenesis procedures, the variable region locations within the vectors can be substituted by a set of palindromic restriction enzyme sites (i.e., two similar sites in opposite orientation). The palindromic sites will loop out and hybridize together during the mutagenesis and thus form a double-stranded substrate for restriction endonuclease digestion. Cleavage of the site results in the destruction of the wild-type template. The variable region of the inserted Hc or Lc sequences will not be affected since they will be in single stranded form.

Following the methods of Example I, single-stranded Hc or Lc populations can be produced by a variety of methods known to one skilled in the art. For example, the PCR primers described in Example I can be used in asymmetric PCR to generate such populations. Gelfand et al., "PCR Protocols: A Guide to Methods and Applications", Ed by M.A. Innis (1990), which is incorporated herein by reference. Asymmetric PCR is a PCR method that differentially amplifies only a single strand of the double

WO 92/06204 PCT/US91/07149

41

Such differential amplification is stranded template. accomplished by decreasing the primer amount for the undesirable strand about 10-fold compared to that for the Alternatively, single-stranded desirable strand. populations can be produced from double-stranded PCR products generated as described in Example I except that the primer(s) used to generate the undesirable strand of the double-stranded products is first phosphorylated at its 5' end with a kinase. The resultant products can then be treated with a 5' to 3' exonuclease, such as lambda exonuclease (BRL, Bethesda, MD) to digest away the unwanted strand.

Single-stranded Hc and Lc populations generated by the methods described above or by others known to one skilled in the art are hybridized to complementary sequences in the previously described vectors. The encoded population of the sequences are subsequently incorporated into a double-stranded form of the vector by polymerase extension of the hybridized templates. Propagation and 20 surface expression of the randomly combined Hc and Lc sequences are performed as described in Example I.

15

been described with Although the invention has reference to the presently preferred embodiment, it should be understood that various modifications can be made 25 without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG 360 TCTTTCGGGC TTCCTCTTAA TCTTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT 420

TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG

CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480
TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAGCCTC	TCGCTATTTT	600
GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720
ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT	780
TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTT	900
CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG	960
AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT	CGTTCCGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTCGA	CACAATTTAT	1140
CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
CAAAGATGAG	TGTTTTAGTG	TATTCTTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCIUG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTC/LGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GCCGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460

GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAGGG	TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTCGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	∜3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACTTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500

TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAATT	AATAACGTTC	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
TCGCTTTCTT	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATTT	CACACGCGTC	ACTTGGCACT	GGCCGTCGTT	TTACAACGTC	6240
GTGACTGGGA	AAACCCTGGC	GTTACCCAAG	CTTTGTACAT	GGAGAAAATA	AAGTGAAACA	6300
AAGCACTATT	GCACTGGCAC	TCTTACCGTT	ACCGTTACTG	TTTACCCCTG	TGACAAAAGC	6360
CGCCCAGGTC	CAGCTGCTCG	AGTCAGGCCT	ATTGTGCCCA	GGGGATTGTA	CTAGTGGATC	6420
CTAGGCTGAA	GGCGATGACC	CTGCTAAGGC	TGCATTCAAT	AGTTTACAGG	CAAGTGCTAC	6480
TGAGTACATT	GGCTACGCTT	GGGCTATGGT	AGTAGTTATA	GTTGGTGCTA	CCATAGGGAT	6540

TAAATTATTC	AAAAAGTTTA	CGAGCAAGGC	TTCTTAAGCA	ATAGCGAAGA	GGCCGCACC	6600
GATCGCCCTT	CCCAACAGTT	GCGCAGCCTG	AATGGCGAAT	GGCGCTTTGC	CTGGTTTCCG	6660
GCACCAGAAG	CGGTGCCGGA	AAGCTGGCTG	GAGTGCGATC	TTCCTGAGGC	CGATACGGTC	6720
STCGTCCCCT	CAAACTGGCA	GATGCACGGT	TACGATGCGC	CCATCTACAC	CAACGTAACC	6780
TATCCCATTA	CGGTCAATCC	GCCGTTTGTT	CCCACGGAGA	ATCCGACGGG	TTGTTACTCG	6840
CTCACATTTA	ATGTTGATGA	AAGCTGGCTA	CAGGAAGGCC	AGACGCGAAT	TATTTTTGAT	6900
GGCGTTCCTA	TTGGTTAAAA	AATGAGCTGA	TTTAACAAAA	ATTTAACGCG	AATTTTAACA	6960
AAATATTAAC	GTTTACAATT	TAAATATTTG	CTTATACAAT	CTTCCTGTTT	TTGGGGCTTT	7020
TCTGATTATC	AACCGGGGTA	CATATGATTG	ACATGCTAGT	TTTACGATTA	CCGTTCATCG	7080
ATTCTCTTGT	TTGCTCCAGA	CTCTCAGGCA	ATGACCTGAT	AGCCTTTGTA	GATCTCTCAA	7140
AAATAGCTAC	CCTCTCCGGC	ATTAATTTAT	CAGCTAGAAC	GGTTGAATAT	CATATTGATG	7200
GTGATTTGAC	TGTCTCCGGC	CTTTCTCACC	CTTTTGAATC	TTTACCTACA	CATTACTCAG	7260
GCATTGCATT	TAAAATATAT	GAGGGTTCTA	AAAATTTTTA	TCCTTGCGTT	GAAATAAAGG	7320
CTTCTCCCGC	AAAAGTATTA	CAGGGTCATA	ATGTTTTTGG	TACAACCGAT	TTAGCTTTAT	7380
GCTCTGAGGC	TTTATTGCTT	AATTTTGCTA	ATTCTTTGCC	TTGCCTGTAT	GATTTATTGG	7440
ACGTT						7445

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7317 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

60	AAATGAAAAT	CTCGCGCCCC	ACCTTTTCAG	AATTGATGCC	CTATTAGTAG	AATGCTACTA
120	TAAATCTACT	ATGGTCAAAC	AATGTATCTA	CCATTTGCGA	AGGTTATTGA	ATAGCTAAAC
180	CCGTACTTTA	CTTCCAGACA	TGGAATGAAA	AACTGTTACA	ATTGGGAATC	CGTTCGCAGA
240	CTCTAAGCCA	AGCAATTAAG	CACCAGATTC	TGAGCTACAG	TAAAACATGT	GTTGCATATT
300	TCCTGACCTG	TACTCTCTAA	CAATTAAAGG	TCAAAAGGAG	TGACCTCTTA	TCCGCAAAAA
360	ATATTTGAAG	TTAAAACGCG	GAAGCTCGAA	GGTTCGCTTT	CTTCCGGTCT	TTGGAGTTTG
420	CTATAATAGT	TTGCTTCTGA	GCAATCCGCT	TCTTTTTGAT	TTCCTCTTAA	TCTTTCGGGC
480	GTTTAAAGCA	TTTCTGAACT	TCATTCTCGT	TGATTTATGG	ACCTGATTTT	CAGGGTAAAG
540	TATCCAGTCT	TATTGGACGC	GATTCCGCAG	TATTTATGAC	ATTCAATGAA	TTTGAGGGGG
600	TCGCTATTTT	CAAAAGCCTC	ACTTCTTTTG	CTCTGGCAAA	CTATTACCCC	AAACATTTTA
660	TATGCCTCGT	TTGCTCTTAC	TATGATAGTG	AAACGAGGGT	GTCGTCTGGT	GGTTTTTATC
720	ATCTCAACTG	GTATTCCTAA	GTTGAATGTG	ATCTGCATTA	GGCGTTATGT	AATTCCTTTT

ATGAATCTTT CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT	780
TCTTCCCAAC GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTT	900
CTCGTCAGGG CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTCGA	CACAATTTAT	1140
CAGGCGATGA TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
CAAAGATGAG TGTTTTAGTG	TATTCTTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT ATACTTATAT	CAACCCTCTC	GACGCCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG	TAAATTCAGA	GACTGCGCTI	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760

TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATG	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTC	GGTATTCCGT	2880
TATTATTGC	TTTCCTCGGI	TTCCTTCTGG	TAACTTTGTT	CGGCTATCT	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAGGG	TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTI	TATGTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA	ATAATATGG	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTCGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACTTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
					TTACTCAAAC	4620
TTAAAATT	AATAACGTTC	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800

AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
TCGCTTTCTT	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CCTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATTT	CACACGCCAA	GGAGACAGTC	ATAATGAAAT	ACCTATTGCC	6240
TACGGCAGCC	GCTGGATTGT	TATTACTCGC	TGCCCAACCA	GCCATGGCCG	AGCTCGTGAT	6300
GACCCAGACT	CCAGATATCC	AACAGGAATG	AGTGTTAATT	CTAGAACGCG	TCACTTGGCA	6360
CTGGCCGTCG	TTTTACAACG	TCGTGACTGG	GAAAACCCTG	GCGTTACCCA	AGCTTAATCG	6420
CCTTGCAGAA	TTCCCTTTCG	CCAGCTGGCG	TAATAGCGAA	GAGGCCCGCA	CCGATCGCCC	6480
TTCCCAACAG	TTGCGCAGCC	TGAATGGCGA	ATGGCGCTTT	GCCTGGTTTC	CGGCACCAGA	6540
AGCGGTGCCG	GAAAGCTGGC	TGGAGTGCGA	TCTTCCTGAG	GCCGATACGG	TCGTCGTCCC	6600
CTCAAACTGG	CAGATGCACG	GTTACGATGC	GCCCATCTAC	ACCAACGTAA	CCTATCCCAT	6660
TACGGTCAAT	CCGCCGTTTG	TTCCCACGGA	GAATCCGACG	GGTTGTTACT	CGCTCACATT	6720
TAATGTTGAT	GAAAGCTGGC	TACAGGAAGG	CCAGACGCGA	ATTATTTTTG	ATGGCGTTCC	6780
TATTGGTTAA	AAAATGAGCT	GATTTAACAA	AAATTTAACG	CGAATTTTAA	CAAAATATTA	6840

ACGTTTACAA TT	TTAAATATT	TGCTTATACA	ATCTTCCTGT	TTTTGGGGCT	TTTCTGATTA	6900
TCAACCGGGG TA	ACATATGAT	TGACATGCTA	GTTTTACGAT	TACCGTTCAT	CGATTCTCTT	6960
GTTTGCTCCA GA	ACTCTCAGG	CAATGACCTG	ATAGCCTTTG	TAGATCTCTC	AAAAATAGCT	7020
ACCCTCTCCG GC	CATTAATTT	ATCAGCTAGA	ACGGTTGAAT	ATCATATTGA	TGGTGATTTG	7080
ACTGTCTCCG GC	CTTTCTCA	CCCTTTTGAA	TCTTTACCTA	CACATTACTC	AGGCATTGCA	7140
TTTAAAATAT AT	GAGGGTTC	TTTTAAAAAT	TATCCTTGCG	TTGAAATAAA	GGCTTCTCCC	7200
GCAAAAGTAT TA	CAGGGTCA	TAATGTTTTT	GGTACAACCG	ATTTAGCTTT	ATGCTCTGAG	7260
GCTTTATTGC TT	AATTTTGC	TAATTCTTTG	CCTTGCCTGT	ATGATTTATT	GGATGTT	7317
(2) INFORMATI	ON FOR SE	O ID NO:3:				

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7729 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT	120
CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA	240
TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	360
TCTTTCGGGC	TTCCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480
TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAGCCTC	TCGCTATTTT	600
GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720
ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT	780
TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTT	900
CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG	960
AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT						1140
CAGGCGATGA						1200

CAAAGATGAG	TGTTTTAGTG	TATTCTTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCTGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAGGG	TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240

CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTCGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGĈG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACTTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAATT	AATAACGTTC	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280

TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
CGGTGGCCTC	ACTGATTATA	ÁAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
TCGCTTTCTT	CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATTT	CACACGCGTC	ACTTGGCACT	GGCCGTCGTT	TTACAACGTC	6240
GTGACTGGGA	AAACCCTGGC	GTTACCCAAG	CTTTGTACAT	GGAGAAAATA	AAGTGAAACA	6300
AAGCACTATT	GCACTGGCAC	TCTTACCGTT	ACTGTTTACC	CCTGTGGCAA	AAGCCCAGGT	6360
CCAGCTGCTC	GAGTCGGTCT	TCCCCCTGGC	ACCCTCCTCC	AAGAGCACCT	CTGGGGGCAC	6420
AGCGGCCCTG	GGCTGCCTGG	TCAAGACTAA	TTCCCCGAAC	CGGTGACGGT	GTCGTGGAAC	6480
TCAGGCGCCC	TGACCAGCGG	CGTGCACACC	TTCCCGGCTG	TCCTACAGTC	CTCAGGACTC	6540
TACTCCCTCA	GCAGCGTGGT	GACCGTGCCC	TCCAGCAGCT	TGGGCACCCA	GACCTACATC	6600
TGCAACGTGA	ATCACAAGCC	CAGCAACACC	AAGGTGGACA	AGAAAGCAGA	GCCCAAATCT	6660
TGTACTAGTG	GATCCTACCC	GTACGACGTT	CC ACTACG	CTTCTTAGGC	TGAAGGCGAT	6720
GACCCTGCTA	AGGCTGCATT	CAATAGTTTA	CAGGCAAGTG	CTACTGAGTA	CATTGGCTAC	6780
GCTTGGGCTA	TGGTAGTAGT	TATAGTTGGT	GCTACCATAG	GGATTAAATT	ATTCAAAAAG	6840
TTTACGAGCA	AGGCTTCTTA	AGCAATAGCG	AAGAGGCCCG	CACCGATCGC	CCTTCCCAAC	6900
AGTTGCGCAG	CCTGAATGGC	GAATGGCGCT	TTGCCTGGTT	TCCGGCACCA	GAAGCGGTGC	6960
CGGAAAGCTG	GCTGGAGTGC	GATCTTCCTG	AGGCCGATAC	GGTCGTCGTC	CCCTCAAACT	7020
GGCAGATGCA	CGGTTACGAT	GCGCCCATCT	ACACCAACGT	AACCTATCCC	ATTACGGTCA	7080
ATCCGCCGTT	TGTTCCCACG	GAGAATCCGA	CGGGTTGTTA	CTCGCTCACA	TTTAATGTIG	7140
ATGAAAGCTG	GCTACAGGAA	GGCCAGACGC	GAATTATTTT	TGATGGCGTT	CCTATTGGTT	7200
AAAAAATGAG	CTGATTTAAC	AAAATTTAA	CGCGAATTTT	AACAAAATAT	TAACGTTTAC	7260
AATTTAAATA	TTTGCTTATA	CAATCTTCCT	GTTTTTGGGG	CTTTTCTGAT	TATCAACCGG	7320

GGTACATATG	ATTGACATGC	TAGTTTTACG	ATTACCGTTC	ATCGATTCTC	TTGTTTGCTC	7380		
CAGACTCTCA	GGCAATGACC	TGATAGCCTT	TGTAGATCTC	TCAAAAATAG	CTACCCTCTC	7440		
CGGCATTAAT	TTATCAGCTA	GAACGGTTGA	ATATCATATT	GATGGTGATT	TGACTGTCTC	7500		
CGGCCTTTCT	CACCCTTTTG	AATCTTTACC	TACACATTAC	TCAGGCATTG	CATTTAAAAT	7560		
ATATGAGGGT	TCTAAAAATT	TTTATCCTTG	CGTTGAAATA	AAGGCTTCTC	CCGCAAAAGT	7620		
ATTACAGGGT	CATAATGTTT	TTGGTACAAC	CGATTTAGCT	TTATGCTCTG	AGGCTTTATT	7680		
GCTTAATTTT	GCTAATTCTT	TGCCTTGCCT	GTATGATTTA	TTGGACGTT		7729		
40.								

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7557 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

60	AAATGAAAAT	CTCGCGCCCC	ACCTTTTCAG	AATTGATGCC	CTATTAGTAG	AATGCTACTA
120	TAAATCTACT	ATGGTCAAAC	AATGTATCTA	CCATTTGCGA	AGGTTATTGA	ATAGCTAAAC
180	CCGTACTTTA	CTTCCAGACA	TGGAATGAAA	AACTGTTACA	ATTGGGAATC	CGTTCGCAGA
240	CTCTAAGCCA	AGCAATTAAG	CACCAGATTC	TGAGCTACAG	TAAAACATGT	GTTGCATATT
300	TCCTGACCTG	TACTCTCTAA	CAATTAAAGG	TCAAAAGGAG	TGACCTCTTA	TCCGCAAAAA
360	ATATTTGAAG	TTAAAACGCG	GAAGCTCGAA	GGTTCGCTTT	CTTCCGGTCT	TTGGAGTTTG
420	CTATAATAGT	TTGCTTCTGA	GCAATCCGCT	TCTTTTTGAT	TTCCTCTTAA	TCTTTCGGGC
480	GTTTAAAGCA	TTTCTGAACT	TCATTCTCGT	TGATTTATGG	ACCTGATTTT	CAGGGTAAAG
540	TATCCAGTCT	TATTGGACGC	GATTCCGCAG	TATTTATGAC	ATTCAATGAA	TTTGAGGGGG
600	TCGCTATTTT	CAAAAGCCTC	ACTTCTTTTG	CTCTGGCAAA	CTATTACCCC	AAACATTTTA
660	TATGCCTCGT	TTGCTCTTAC	TATGATAGTG	AAACGAGGGT	GTCGTCTGGT	GGTTTTTATC
720	ATCTCAACTG	GTATTCCTAA	GTTGAATGTG	ATCTGCATTA	GGCGTTATGT	AATTCCTTTT
780	CGTAGATTTT	GTTTTATTAA	CCGTTAGTTC	TAATGTTGTT	CTACCTGTAA	ATGAATCTTT
840	AGGTAATTCA	AAATCGCATA	CCAGTTCTTA	GTATAATGAG	GTCCTGACTG	TCTTCCCAAC
900	TCTGGTGTTT	TACTACTCGT	AAGCCCAATT	AAACCATCTC	AGTTGAAATT	CAATGATTAA
960	TTGGGTAATG	TTACGTTGAT	AGCAGCTTTG	TCACTGAATG	CAAGCCTTAT	CTCGTCAGGG
1020	GCGCCTGGTC	GCCAGCCTAT	ATGAAGGTCA	ATTACTCTTG	TCTTGTCAAG	AATATCCGGT
1080	ATGATTGACC	CGGTTCCCTT	TTGGTCAGTT	TCTTTCAAAG	TCATCTGTCC	TGTACACCGT
1140	CACAATTTAT	CGGATTTCGA	GAGCAGGTCG	AAGTAACATG	CGTTCCGGCT	GTCTGCGCCT
1200	CGCTGGGGGT	TTGGTATAAT	TGTTTCGCGC	CGTTGTACTT	TACAAATCTC	CAGGCGATGA
1260	TGCCTTCGTA	TTTAGGTTGG	CCTCTTTCGT	TATTCTTTCG	TGTTTTAGTG	- CAAAGATGAG

GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CCTGTTTCTT	GCTCTTATTA	TTGGGCTTAA	3000
CTCAATTCTT	GTGGGTTATC	TCTCTGATAT	TAGCGCTCAA	TTACCCTCTG	ACTTTGTTCA	3060
GGGTGTTCAG	TTAATTCTCC	CGTCTAATGC	GCTTCCCTGT	TTTTATGTTA	TTCTCTCTGT	3120
AAAGGCTGCT	ATTTTCATTT	TTGACGTTAA	ACAAAAAATC	GTTTCTTATT	TGGATTGGGA	3180
TAAATAATAT	GGCTGTTTAT	TTTGTAACTG	GCAAATTAGG	CTCTGGAAAG	ACGCTCGTTA	3240
GCGTTGGTAA	GATTCAGGAT	AAAATTGTAG	CTGGGTGCAA	AATAGCAACT	AATCTTGATT	3300

TAAGGCTTCA	AAACCTCCCG	CAAGTCGGGA	GGTTCGCTAA	AACGCCTCGC	GTTCTTAGAA	3360
TACCGGATAA	GCCTTCTATA	TCTGATTTGC	TTGCTATTGG	GCGCGGTAAT	GATTCCTACG	3420
ATGAAAATAA	AAACGGCTTG	CTTGTTCTCG	ATGAGTGCGG	TACTTGGTTT	AATACCCGTT	3480
CTTGGAATGA	TAAGGAAAGA	CAGCCGATTA	TTGATTGGTT	TCTACATGCT	CGTAAATTAG	3540
GATGGGATAT	TATTTTTCTT	GTTCAGGACT	TATCTATTGT	TGATAAACAG	GCGCGTTCTG	3600
CATTAGCTGA	ACATGTTGTT	TATTGTCGTC	GTCTGGACAG	AATTACTTTA	CCTTTTGTCG	3660
GTACTTTATA	TTCTCTTATT	ACTGGCTCGA	AAATGCCTCT	GCCTAAATTA	CATGTTGGCG	3720
TTGTTAAATA	TGGCGATTCT	CAATTAAGCC	CTACTGTTGA	GCGTTGGCTT	TATACTGGTA	3780
AGAATTTGTA	TAACGCATAT	GATACTAAAC	AGGCTTTTTC	TAGTAATTAT	GATTCCGGTG	3840
TTTATTCTTA	TTTAACGCCT	TATTTATCAC	ACGGTCGGTA	TTTCAAACCA	TTAAATTTAG	3900
GTCAGAAGAT	GAAGCTTACT	AAAATATATT	TGAAAAAGTT	TTCACGCGTT	CTTTGTCTTG	3960
CGATTGGATT	TGCATCAGCA	TTTACATATA	GTTATATAAC	CCAACCTAAG	CCGGAGGTTA	4020
AAAAGGTAGT	CTCTCAGACC	TATGATTTTG	ATAAATTCAC	TATTGACTCT	TCTCAGCGTC	4080
TTAATCTAAG	CTATCGCTAT	GTTTTCAAGG	ATTCTAAGGG	AAAATTAATT	AATAGCGACG	4140
ATTTACAGAA	GCAAGGTTAT	TCACTCACAT	ATATTGATTT	ATGTACTGTT	TCCATTAAAA	4200
AAGGTAATTC	AAATGAAATT	GTTAAATGTA	ATTAATTTTG	TTTTCTTGAT	GTTTGTTTCA	4260
TCATCTTCTT	TTGCTCAGGT	AATTGAAATG	AATAATTCGC	CTCTGCGCGA	TTTTGTAACT	4320
TGGTATTCAA	AGCAATCAGG	CGAATCCGTT	ATTGTTTCTC	CCGATGTAAA	AGGTACTGTT	4380
ACTGTATATT	CATCTGACGT	TAAACCTGAA	AATCTACGCA	ATTTCTTTAT	TTCTGTTTTA	4440
CGTGCTAATA	ATTTTGATAT	GGTTGGTTCA	ATTCCTTCCA	TAATTCAGAA	GTATAATCCA	4500
AACAATCAGG	ATTATATTGA	TGAATTGCCA	TCATCTGATA	ATCAGGAATA	TGATGATAAT	4560
TCCGCTCCTT	CTGGTGGTTT	CTTTGTTCCG	CAAAATGATA	ATGTTACTCA	AACTTTTAAA	4620
ATTAATAACG	TTCGGGCAAA	GGATTTAATA	CGAGTTGTCG	AATTGTTTGT	AAAGTCTAAT	4680
ACTTCTAAAT	CCTCAAATGT	ATTATCTATT	GACGGCTCTA	ATCTATTAGT	TGTTAGTGCA	4740
CCTAAAGATA	TTTTAGATAA	CCTTCCTCAA	TTCCTTTCTA	CTGTTGATTT	GCCAACTGAC	4800
CAGATATTGA	TTGAGGGTTT	GATATTTGAG	GTTCAGCAAG	GTGATGCTTT	AGATTTTTCA	4860
	GCTCTCAGCG					4920
TCTGTTTTAT	CTTCTGCTGG	TGGTTCGTTC	GGTATTTTTA	ATGGCGATGT	TTTAGGGCTA	4980
TCAGTTCGCG	CATTAAAGAC	TAATAGCCAT	TCAAAAATAT	TGTCTGTGCC	ACGTATTCTT	5040
	GTCAGAAGGG					5100
	GTGAATCTGC					5160
					TGTTCTGGAT	5220
ATTACCAGCA	AGGCCGATAG	TTTGAGTTCT	TCTACTCAGG	CAAGTGATGT	TATTACTAAT	5280
CAAAGAAGTA	TTGCTACAAC	GGTTAATTTG	CGTGATGGAC	AGACTCTTTT	ACTCGGTGGC	53/10

CTCACTGATT	ATAAAAACAC	TTCTCAAGA~	TCTGGCGTAC	CGTTCCTGTC	TAAAATCCCT	5400
TTAATCGGCC	TCCTGTTTAG	CTCCCGCTCT	GATTCCAACG	AGGAAAGCAC	GTTATACGTG	5460
CTCGTCAAAG	CAACCATAGT	ACGCGCCCTG	TAGCGGCGCA	TTAAGCGCGG	CGGGTGTGGT	5520
GGTTACGCGC	AGCGTGACCG	CTACACTTGC	CAGCGCCCTA	GCGCCCGCTC	CTTTCGCTTT	5580
CTTCCCTTCC	TTTCTCGCCA	CGTTCGCCGG	CTTTCCCCGT	CAAGCTCTAA	ATCGGGGGCT	5640
CCCTTTAGGG	TTCCGATTTA	GTGCTTTACG	GCACCTCGAC	CCCAAAAAAC	TTGATTTGGG	5700
TGATGGTTCA	CGTAGTGGGC	CATCGCCCTG	ATAGACGGTT	TTTCGCCCTT	TGACGTTGGA	5760
GTCCACGTTC	TTTAATAGTG	GACTCTTGTT	CCAAACTGGA	ACAACACTCA	ACCCTATCTC	5820
GGGCTATTCT	TTTGATTTAT	AAGGGATTTT	GCCGATTTCG	GAACCACCAT	CAAACAGGAT	5880
TTTCGCCTGC	TGGGGCAAAC	CAGCGTGGAC	CGCTTGCTGC	AACTCTCTCA	GGGCCAGGCG	5940
GTGAAGGGCA	ATCAGCTGTT	GCCCGTCTCG	CTGGTGAAAA	GAAAAACCAC	CCTGGCGCCC	6000
AATACGCAAA	CCGCCTCTCC	CCGCGCGTTG	GCCGATTCAT	TAATGCAGCT	GGCACGACAG	6060
GTTTCCCGAC	TGGAAAGCGG	GCAGTGAGCG	CAACGCAATT	AATGTGAGTT	AGCTC# 7A	6120
TTAGGCACCC	CAGGCTTTAC	ACTTTATGCT	TCCGGCTCGT	ATGTTGTGTG	GAATTG'LUAG	6180
CGGATAACAA	TTTCACACGC	CAAGGAGACA	GTCATAATGA	AATACCTATT	GCCTACGGCA	6240
GCCGCTGGAT	TGTTATTACT	CGCTGCCCAA	CCAGCCATGG	CCGAGCTCTT	CCCGCCATCT	6300
GATGAGCAGT	TGAAATCTGG	AACTGCCTCT	GTTGTGTGCC	TGCTGAATAA	CTTCTATCCC	6360
AGAGAGGCCA	AAGTACAGTG	GAAGGTGGAT	AACGCCCTCC	AATCGGGTAA	CTCCCAGGAG	6420
AGTGTCACAG	AGCAGGACAG	CAAGGACAGC	ACCTACAGCC	TCAGCAGCAC	CCTGACGCTG	6480
AGCAAAGCAG	ACTACGAGAA	ACACAAAGTC	TACGCCTGCG	AAGTCACCCA	TCAGGGCCTG	6540
AGCTCGCCCG	TCACAAAGAG	CTTCAACAGG	GGAGAGTGTT	CTAGAACGCG	TCACTTGGCA	6600
CTGGCCGTCG	TTTTACAACG	TCGTGACTGG	GAAAACCCTG	GCGTTACCCA	AGCTTAATCG	6660
CCTTGCAGAA	TTCCCTTTCG	CCAGCTGGCG	TAATAGCGAA	GAGGCCCGCA	CCGATCGCCC	6720
TTCCCAACAG	TTGCGCAGCC	TGAATGGCGA	ATGGCGCTTT	GCCTGGTTTC	CGGCACCAGA	6780
AGCGGTGCCG	GAAAGCTGGC	TGGAGTGCGA	TCTTCCTGAG	GCCGATACGG	TCGTCGTCCC	6840
CTCAAACTGG	CAGATGCACG	GTTACGATGC	GCCCATCTAC	ACCAACGTAA	CCTATCCCAT	6900
TACGGTCAAT	CCGCCGTTTG	TTCCCACGGA	GAATCCGACG	GGTTGTTACT	CGCTCACATT	6960
TAATGTTGAT	GAAAGCTGGC	TACAGGAAGG	CCAGACGCGA	ATTATTTTTG	ATGGCGTTCC	7020
TATTGGTTAA	AAAATGAGCT	GATTTAACAA	AAATTTAACG	CGAATTTTAA	CAAAATATTA	7080
ACGTTTACAA	TTTAAATATT	TGCTTATACA	ATCTTCCTGT	TTTTGGGGCT	TTTCTGATTA	7140
TCAACCGGGG	TACATATGAT	TGACATGCTA	GTTTTACGAT	TACCGTTCAT	CGATTCTCTT	7200
GTTTGCTCCA	GACTCTCAGG	CAATGACCTG	ATAGCCTTTG	TAGATCTCTC	AAAAATAGCT	7260
ACCCTCTCCG	GCATTAATTT	ATCAGCTAGA	ACGGTTGAAT	ATCATATTGA	TGGTGATTTG	7320
ACTGTCTCCG	GCCTTTCTCA	CCCTTTTGAA	TCTTTACCTA	CACATTACTC	AGGCATTGCA	7380

WO 92/06204 PCT/US91/07149

58

TTTAAAATAT ATGAGGGTTC TAAAAATTTT TATCCTTGCG TTGAAATAAA GGCTTCTCCC 7440 GCAAAAGTAT TACAGGGTCA TAATGTTTTT GGTACAACCG ATTTAGCTTT ATGCTCTGAG 7500 GCTTTATTGC TAATTTTGC TAATTCTTTG CCTTGCCTGT ATGATTTATT GGATGTT 7557

(2) INFORMATION FOR SEQ ID NO:5:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8118 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

			•		•	, ,
60	AAATGAAAAT	CTCGCGCCCC	ACCTTTTCAG	AATTGATGCC	CTATTAGTAG	AATGCTACTA
120	TAAATCTACT	ATGGTCAAAC	AATGTATCTA	CCATTTGCGA	AGGTTATTGA	ATAGCTAAAC
180	CCGTACTTTA	CTTCCAGACA	TGGAATGAAA	AACTGTTACA	ATTGGGAATC	CGTTCGCAGA
240	CTCTAAGCCA	AGCAATTAAG	CACCAGATTC	TGAGCTACAG	TAAAACATGT	GTTGCATATT
300	TCCTGACCTG	TACTCTCTAA	CAATTAAAGG	TCAAAAGGAG	TGACCTCTTA	TCTGCAAAAA
360	ATATTTGAAG	TTAAAACGCG	GAAGCTCGAA	GGTTCGCTTT	CTTCCGGTCT	TTGGAGTTTG
420	CTATAATAGT	TTGCTTCTGA	GCAATCCGCT	TCTTTTTGAT	TTCCTCTTAA	TCTTTCGGGC
480	GTTTAAAGCA	TTTCTGAACT	TCATTCTCGT	TGATTTATGG	ACCTGATTTT	CAGGGTAAAG
540	TATCCAGTCT	TATTGGACGC	GATTCCGCAG	TATTTATGAC	ATTCAATGAA	TTTGAGGGGG
600	TCGCTATTTT	CAAAAGCCTC	ACTTCTTTTG	CTCTGGCAAA	CTATTACCCC	AAACATTTTA
660	TATGCCTCGT	TTGCTCTTAC	TATGATAGTG	AAACGAGGGT	GTCGTCTGGT	GGTTTTTATC
720	ATCTCAACTG	GTATTCCTAA	GTTGAATGTG	ATCTGCATTA	GGCGTTATGT	AATTCCTTTT
780	CGTAGATTTT	GTTTTATTAA	CCGTTAGTTC	TAATGTTGTT	CTACCTGTAA	ATGAATCTTT
840	AGGTAATTCA	AAATCGCATA	CCAGTTCTTA	GTATAATGAG	GTCCTGACTG	TCTTCCCAAC
900	TCTGGTGTTT	TACTACTCGT	AAGCCCAATT	AAACCATCTC	AGTTGAAATT	CAATGATTAA
960	TTGGGTAATG	TTACGTTGAT	AGCAGCTTTG	TCACTGAATG	CAAGCCTTAT	CTCGTCAGGG
1020	GCGCCTGGTC	GCCAGCCTAT	ATGAAGGTCA	ATTACTCTTG	TCTTGTCAAG	AATATCCGGT
1080	ATGATTGACC	CGGTTCCCTT	TTGGTCAGTT	TCTTTCAAAG	TCATCTGTCC	TGTACACCGT
1140	CACAATTTAT	CGGATTTCGA	GAGCAGGTCG	AAGTAACATG	CGTTCCGGCT	GTCTGCGCCT
1200	CGCTGGGGGT	TTGGTATAAT	TGTTTCGCGC	CGTTGTACTT	TACAAATCTC	CAGGCGATGA
1260	TGCCTTCGTA	TTTAGGTTGG	CCTCTTTCGT	TATTCTTTCG	TGTTTTAGTG	CAAAGATGAG
1320	CTTTAGTCCT	ATGAAAAAGT	AAACTTCCTC	CGTTTAATGG	GTATTTTACC	GTGGCATTAC
1380	CTGAGGGTGA	TCTTTCGCTG	TCCGATGCTG	CTACCCTCGT	GTAGCCGTTG	CAAAGCCTCT
1440	ATATCGGTTA	GCGACCGAAT	GCAAGCCTCA	TTAACTCCCT	AAAGCGGCCT	CGATCCCGCA
1500	TGTTTAAGAA	GGTATCAAGC	CGCAACTATC	TCATTGTCGG	ATGGTTGTTG	TGCGTGGGCG

ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA	TTGGGCTTGC	TATCCCTGAA	AATGAGGGTG	GTGGCTCTGA	GGGTGGCGGT	1860
TCTGAGGGTG	GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCGCTA	ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA	GGTTCCGAAA	TAGGCAGGGG	GCATTAACTG	TTTATACGGG	CACTGTTACT	2100
CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG	2160
TATGACGCTT	ACTGGAACGG	TAAATTCAGA	GACTGCGCTT	TCCATTCTGG	CTTTAATGAA	2220
GATCCATTCG	TTTGTGAATA	TCAAGGCCAA	TCGTCTGACC	TGCCTCAACC	TCCTGTCAAT	2280
GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT	2340
GGCGGTTCTG	AGGGTGGCGG	CTCTGAGGGA	GGCGGTTCCG	GTGGTGGCTC	TGGTTCCGGT	2400
GATTTTGATT	ATGAAAAGAT	GGCAAACGCT	AATAAGGGGG	CTATGACCGA	AAATGCCGAT	2460
GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT	2520
GCTGCTATCG	ATGGTTTCAT	TGGTGACGTT	TCCGGCCTTG	CTAATGGTAA	TGGTGCTACT	2580
GGTGATTTTG	CTGGCTCTAA	TTCCCAAATG	GCTCAAGTCG	GTGACGGTGA	TAATTCACCT	2640
TTAATGAATA	ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT	2700
TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA	TTTTCTATTG	ATTGTGACAA	AATAAACTTA	2760
TTCCGTGGTG	TCTTTGCGTT	TCTTTTATAT	GTTGCCACCT	TTATGTATGT	ATTTTCTACG	2820
TTTGCTAACA	TACTGCGTAA	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT	2880
TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC	2940
TTAAAAAGGG	CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	GTTTCTTGCT	CTTATTATTG	3000
GGCTTAACTC	AATTCTTGTG	GGTTATCTCT	CTGATATTAG	CGCTCAATTA	CCCTCTGACT	3060
TTGTTCAGGG	TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC	3120
TCTCTGTAAA	GGCTGCTATT	TTCATTTTTG	ACGTTAAACA	AAAAATCGTT	TCTTATTTGG	3180
ATTGGGATAA	ATAATATGGC	TGTTTATTTT	GTAACTGGCA	AATTAGGCTC	TGGAAAGACG	3240
CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTTGCTTG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540

AAATTAGGAT	GGGATATTAT	TTTTCTTGTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTCGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TTGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACTTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	ATTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAATT	AATAACGTTC	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT	GTTTTATCTT	CTGCTGGTGG	TTCGTTCGGT	ATTTTTAATG	GCGATGTTTT	4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
TCTGGATATT	ACCAGCAAGG	CCGATAGTTT	GAGTTCTTCT	ACTCAGGCAA	GTGATGTTAT	5280
TACTAATCAA	AGAAGTATTG	CTACAACGGT	TAATTTGCGT	GATGGACAGA	CTCTTTTACT	5340
CGGTGGCCTC	ACTGATTATA	AAAACACTTC	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
AATCCCTTTA	ATCGGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
ATACGTGCTC	GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	5520
GTGTGGTGGT	TACGCCCAGC	GTGACCCCTA	CACTTCCCAC	CCCCCTACCC	CCCCCTCCTT	5500

TCGCTTTCTT	CCCTTCCTTI	CTCGCCACGI	TCGCCGGCTI	TCCCCGTCAA	GCTCTAAATC	5640
GGGGGCTCCC	TTTAGGGTTC	CGATTTAGTG	CTTTALGGCA	CCTCGACCC	AAAAAACTTG	5700
ATTTGGGTGA	TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CGTTGGAGTC	CACGTTCTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG	CTATTCTTTT	GATTTATAAG	GGATTTTGCC	GATTTCGGAA	CCACCATCAA	5880
ACAGGATTTT	CGCCTGCTGG	GGCAAACCAG	CGTGGACCGC	TTGCTGCAAC	TCTCTCAGGG	5940
CCAGGCGGTG	AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
GGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTTGGCC	GATTCATTAA	TGCAGCTGGC	6060
ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA	CGCAATTAAT	GTGAGTTAGC	6120
TCACTCATTA	GGCACCCCAG	GCTTTACACT	TTATGCTTCC	GGCTCGTATG	TTGTGTGGAA	6180
TTGTGAGCGG	ATAACAATTT	CACACGCCAA	GGAGACAGTC	ATAATGAAAT	ACCTATTGCC	6240
TACGGCAGCC	GCTGGATTGT	TATTACTCGC	TGCCCAACCA	GCCATGGCCG	AGCTCTTCCC	6300
GCCATCTGAT	GAGCAGTTGA	AATCTGGAAC	TGCCTCTGTT	GTGTGCCTGC	TGAATAACTT	6360
CTATCCCAGA	GAGGCCAAAG	TACAGTGGAA	GGTGGATAAC	GCCCTCCAAT	CGGGTAACTC	6420
CCAGGAGAGT	GTCACAGAGC	AGGACAGCAA	GGACAGCACC	TACAGCCTCA	GCAGCACCCT	6480
GACGCTGAGC	AAAGCAGACT	ACGAGAAACA	CAAAGTCTAC	GCCTGCGAAG	TCACCCATCA	6540
GGGCCTGAGC	TCGCCCGTCA	CAAAGAGCTT	CAACAGGGGA	GAGTGTTCTA	GAACGCGTCA	6600
CTTGGCACTG	GCCGTCGTTT	TACAACGTCG	TGACTGGGAA	AACCCTGGCG	TTACCCAAGC	6660
TTTGTACATG	GAGAAAATAA	AGTGAAACAA	AGCACTATTG	CACTGGCACT	CTTACCGTTA	6720
CTGTTTACCC	CTGTGGCAAA	AGCCGCCTCC	ACCAAGGGCC	CATCGGTCTT	CCCCTGGCA	6780
CCCTCCTCCA	AGAGCACCTC	TGGGGGCACA	GCGGCCCTGG	GCTGCCTGGT	CAAGACTAAT	6840
TCCCCGAACC	GGTGACGGTG	TCGTGGAACT	CAGGCGCCCT	GACCAGCGGC	GTGCACACCT	6900
TCCCGGCTGT	CCTACAGTCC	TCAGGACTCT	ACTCCCTCAG	CAGCGTGGTG	ACCGTGCCCT	6960
CCAGCAGCTT	GGGCACCCAG	ACCTACATCT	GCAACGTGAA	TCACAAGCCC	AGCAACACCA	7020
AGGTGGACAA	GAAAGCAGAG	CCCAAATCTT	GTACTAGTGG	ATCCTACCCG	TACGACGTTC	7080
CGGACTACGC	TTCTTAGGCT	GAAGGCGATG	ACCCTGCTAA	GGCTGCATTC	AATAGTTTAC	7140
AGGCAAGTGC	TACTGAGTAC	ATTGGCTACG	CTTGGGCTAT	GGTAGTAGTT	ATAGTTGGTG	7200
CTACCATAGG	GATTAAATTA	TTCAAAAAGT	TTACGAGCAA	GGCTTCTTAA	GCAATAGCGA	7260
AGAGGCCCGC	ACCGATCGCC	CTTCCCAACA	GTTGCGCAGC	CTGAATGGCG	AATGGCGCTT	7320
TGCCTGGTTT	CCGGCACCAG	AAGCGGTGCC	GGAAAGCTGG	CTGGAGTGCG	ATCTTCCTGA	7380
GGCCGATACG	GTCGTCGTCC	CCTCAAACTG	GCAGATGCAC	GGTTACGATG	CGCCCATCTA	7440
CACCAACGTA	ACCTATCCCA	TTACGGTCAA	TCCGCCGTTT	GTTCCCACGG	AGAATCCGAC	7500
GGGTTGTTAC	TCGCTCACAT	TTAATGTTGA	TGAAAGCTGG	CTACAGGAAG	GCCAGACGCG	7560
ΔΑΤΤΑΤΤΤΤΤ	GATGGCGTTC	CTATTGGTTA	AAAATGAGC	TCATTTAACA	AAAATTTAAC	7620

GCGAATTTTA	ACAAAATATT	AACGTTTACA	ATTTAAATAT	TTGCTTATAC	AATCTTCCTG	7680
TTTTTGGGGC	TTTTCTGATT	ATCAACCGGG	GTACATATGA	TTGACATGCT	AGTTTTACGA	7740
TTACCGTTCA	TCGATTCTCT	TGTTTGCTCC	AGACTCTCAG	GCAATGACCT	GATAGCCTTT	7800
GTAGATCTCT	CAAAAATAGC	TACCCTCTCC	GGCATTAATT	TATCAGCTAG	AACGGTTGAA	7860
TATCATATTG	ATGGTGATTT	GACTGTCTCC	GGCCTTTCTC	ACCCTTTTGA	ATCTTTACCT	7920
ACACATTACT	CAGGCATTGC	ATTTAAAATA	TATGAGGGTT	CTAAAAATTT	TTATCCTTGC	7980
GTTGAAATAA	AGGCTTCTCC	CGCAAAAGTA	TTACAGGGTC	ATAATGTTTT	TGGTACAACC	8040
GATTTAGCTT	TATGCTCTGA	GGCTTTATTG	CTTAATTTTG	CTAATTCTTT	GCCTTGCCTG	8100
TATGATTTAT	TGGACGTT					8118

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc_difference
 (B) LOCATION: replace(5, "")
 (D) OTHER INFORMATION: /note- "S REPRESENTS EQUAL MIXTURE OF G AND C"

(ix) FEATURE:

- (A) NAME/KEY: misc difference
- (B) LOCATION: replace(6, "")
- (D) OTHER INFORMATION: /note- "M REPRESENTS EQUAL MIXTURE OF A AND C"

(ix) FEATURE:

į

- (A) NAME/KEY: misc_difference
- (B) LOCATION: replace(8, "")
- (D) OTHER INFORMATION: /note- "R REPRESENTS EQUAL MIXTURE OF A AND G"

(ix) FEATURE:

- (A) NAME/KEY: misc_difference
- (B) LOCATION: replace(11, "")
- (D) OTHER INFORMATION: /note- "K REPRESENTS EQUAL MIXTURE OF G AND T"

(ix) FEATURE:

- (A) NAME/KEY: misc_difference
 (B) LOCATION: replace(20, "")
- (D) OTHER INFORMATION: /note= "W REPRESENTS EQUAL MIXTURE OF A AND T"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGGTSMARCT KCTCGAGTCW GG

.

(2) INFORMATION FOR SEQ ID NO:7:	•
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:	
AGGTCCAGCT GCTCGAGTCT GG	22
(2) INFORMATION FOR SEQ ID NO:8:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:	
AGGTCCAGCT GCTCGAGTCA GG	22
(2) INFORMATION FOR SEQ ID NO:9:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	,
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:	i.
AGGTCCAGCT TCTCGAGTCT GG	22
(2) INFORMATION FOR SEQ ID NO:10:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:	,
AGGTCCAGCT TCTCGAGTCA GG	22
(2) INFORMATION FOR SEQ ID NO:11:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:	
AGGTCCAACT GCTCGAGTCT GG	22
(2) INFORMATION FOR SEQ ID NO:12:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:	
AGGTCCAACT GCTCGAGTCA GG	22
(2) INFORMATION FOR SEQ ID NO:13:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:	
AGGTCCAACT TCTCGAGTCT GG	22
(2) INFORMATION FOR SEQ ID NO:14:	
(1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:14:	
AGGTCCAACT TCTCGAGTCA GG	22
(2) INFORMATION FOR SEQ ID NO:15:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
<pre>(ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(56, "") (D) OTHER INFORMATION: /note= "N=INOSINE"</pre>	
<pre>(ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(8, "") (D) OTHER INFORMATION: /note= "N=INOSINE"</pre>	

<pre>(ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(11, "") (D) OTHER INFORMATION: /note= "N=INOSINE"</pre>	
(ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(20, "") (D) OTHER INFORMATION: /note= "W REPRESENTS EQUAL MIXTURE OF A AND T"	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:	
AGGINNANCI NCICGAGICW GG	22
(2) INFORMATION FOR SEQ ID NO:16:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:	
CTATTAACTA GTAACGGTAA CAGTGGTGCC TTGCCCCA	38
(2) INFORMATION FOR SEQ ID NO:17:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:	
AGGCTTACTA GTACAATCCC TGGGCACAAT	30
(2) INFORMATION FOR SEQ ID NO:18:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:	
CCAGTTCCGA GCTCGTTGTG ACTCAGGAAT CT	32
(2) INFORMATION FOR SEQ ID NO:19:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:	
CCAGTTCCGA GCTCGTGTTG ACGCAGCCGC CC	32
(2) INFORMATION FOR SEQ ID NO:20:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:	
CCAGTTCCGA GCTCGTGCTC ACCCAGTCTC CA	32
(2) INFORMATION FOR SEQ ID NO:21:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:	
CCAGTTCCGA GCTCCAGATG ACCCAGTCTC CA	32
(2) INFORMATION FOR SEQ ID NO:22:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
. Name of the state of the stat	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:	
CCAGATGTGA GCTCGTGATG ACCCAGACTC CA	32
(2) INFORMATION FOR SEQ ID NO:23:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:	
CCAGATGTGA GCTCGTCATG ACCCAGTCTC CA	32
(2) INFORMATION FOR SEQ ID NO:24:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:	
CCAGTTCCGA GCTCGTGATG ACACAGTCTC CA	32
(2) INFORMATION FOR SEQ ID NO:25:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:25:	
GCAGCATTCT AGAGTTTCAG CTCCAGCTTG CC	32
(2) INFORMATION FOR SEQ ID NO:26:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:26:	
GCGCCGTCTA GAATTAACAC TCATTCCTGT TGAA	34
(2) INFORMATION FOR SEQ ID NO:27:	
(1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:	
GATCCTAGGC TGAAGGCGAT GACCCTGCTA AGGCTGC	37
(2) INFORMATION FOR SEQ ID NO:28:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:	
ATTCAATAGT TTACAGGCAA GTGCTACTGA GTACA	35

(2) INFORMATION FOR SEQ ID NO:29:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
\cdot	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:	
TTGGCTACGC TTGGGCTATG GTAGTAGTTA TAGTT	35
(2) INFORMATION FOR SEQ ID NO:30:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:	
GGTGCTACCA TAGGGATTAA ATTATTCAAA AAGTT	35
(2) INFORMATION FOR SEQ ID NO:31:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:	
TACGAGCAAG GCTTCTTA	18
(2) INFORMATION FOR SEQ ID NO:32:	10
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:	
AGCTTAAGAA GCCTTGCTCG TAAACTTTTT GAATAATTT	39
(2) INFORMATION FOR SEQ ID NO:33:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

(xi)) SEQUENCE DESCRIPTION: SEQ ID NO:33:	
AATCCCTA	ATG GTAGCACCAA CTATAACTAC TACCAT	36
(2) INFO	ORMATION FOR SEQ ID NO:34:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi)) SEQUENCE DESCRIPTION: SEQ ID NO:34:	
AGCCCAAG	GCG TAGCCAATGT ACTCAGTAGC ACTTG	35
(2) INFO	ORMATION FOR SEQ ID NO:35:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi)) SEQUENCE DESCRIPTION: SEQ ID NO:35:	
CCTGTAA	CT ATTGAATGCA GCCTTAGCAG GGTC	34
(2) INFO	ORMATION FOR SEQ ID NO:36:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:36:	
ATCGCCTT	TCA GCCTAG	16
(2) INFO	DRMATION FOR SEQ ID NO:37:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:37:	
CATTTTTG	GCA GATGGCTTAG A	21
(2) INFO	DRMATION FOR SEQ ID NO:38:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:	
TAGCATTAAC GTCCAATA	18
(2) INFORMATION FOR SEQ ID NO:39:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:	
ATATATTTA GTAAGCTTCA TCTTCT	26
(2) INFORMATION FOR SEQ ID NO:40:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:	23
	23
(2) INFORMATION FOR SEQ ID NO:41:	•
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:	
GCGGGCCTCT TCGCTATTGC TTAAGAAGCC TTGCT	35
(2) INFORMATION FOR SEQ ID NO:42:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:	
AAACGACGGC CAGTGCCAAG TGACGCGTGT GAAATTGTTA TCC	43

(2) INFORMATION FOR SEQ ID NO:43:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:	
GGCGAAAGGG AATTCTGCAA GGCGATTAAG CTTGGGTAAC GCC	43
(2) INFORMATION FOR SEQ ID NO:44:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:	
GGCGTTACCC AAGCTTTGTA CATGGAGAAA ATAAAG	36
(2) INFORMATION FOR SEQ ID NO:45:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x: SEQUENCE DESCRIPTION: SEQ ID NO:45:	
TGAAACAAAG CACTATTGCA CTGGCACTCT TACCGTTACC GT	42
(2) INFORMATION FOR SEQ ID NO:46:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:	
TACTGTTTAC CCCTGTGACA AAAGCCGCCC AGGTCCAGCT GC	42
(2) INFORMATION FOR SEQ ID NO:47:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

S.

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:	
	TCGAGTCAGG CCTATTGTGC CCAGGGATTG TACTAGTGGA TCCG	44
	(2) INFORMATION FOR SEQ ID NO:48:	
	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:	
	TGGCGAAAGG GAATTCGGAT CCACTAGTAC AATCCCTG	38
	(2) INFORMATION FOR SEQ ID NO:49:	
	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(x1) SEQUENCE DESCRIPTION: SEQ ID NO:49:	
	GGCACAATAG GCCTGACTCG AGCAGCTGGA CCAGGGCGGC TT	42
	(2) INFORMATION FOR SEQ ID NO:50:	
	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
•	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:	
	TTGTCACAGG GGTAAACAGT AACGGTAACG GTAAGTGTGC CA	42
	(2) INFORMATION FOR SEQ ID NO:51:	
	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:	
	GTGCAATAGT GCTTTGTTTC ACTTTATTTT CTCCATGTAC AA	42
	(2) INFORMATION FOR SEQ ID NO:52:	
	 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:	
TAACGGTAAG AGTGCCAGTG C	21
(2) INFORMATION FOR SEQ ID NO:53:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:	
CACCTTCATG AATTCGGCAA GGAGACAGTC AT	_ 32
(2) INFORMATION FOR SEQ ID NO:54:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:	22
(2) INFORMATION FOR SEQ ID NO:55:	
 (1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	XXXX.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:	
AATGAAATAC CTATTGCCTA CGGCAGCCGC TGGATTGTT	39
(2) INFORMATION FOR SEQ ID NO:56:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:	
ATTACTCCCT GCCGAACCAG CCATGGCCGA GCTCGTGAT	39

(2) INFORMATION FOR SEQ ID NO:57:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:	
GACCCAGACT CCAGATATCC AACAGGAATG AGTGTTAAT	39
(2) INFORMATION FOR SEQ ID NO:58:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:	
TCTAGAACGC GTC	13
(2) INFORMATION FOR SEQ ID NO:59:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:	
TTCAGGTTGA AGCTTACGCG TTCTAGAATT AACACTCATT CCTGT	45
(2) INFORMATION FOR SEQ ID NO:60:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:	
TGGATATCTG GAGTCTGGGT CATCACGAGC TCGGCCATG	39
(2) INFORMATION FOR SEQ ID NO:61:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:	
GCTGGTTGGG CAGCGAGTAA TAACAATCCA GCGGCTGCC	39
(2) INFORMATION FOR SEQ ID NO:62:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:	
GTAGGCAATA GGTATTTCAT TATGACTGTC CTTGGCG	37
(2) INFORMATION FOR SEQ ID NO:63:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:	
TGACTGTCTC CTTGGCGTGT GAAATTGTTA	30
(2) INFORMATION FOR SEQ ID NO:64:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:	
TAACACTCAT TCCGGATGGA ATTCTGGAGT CTGGGT	36
(2) INFORMATION FOR SEQ ID NO:65:	•
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:	
GCCAGTGCCA AGTGACGCGT TCTA	24
(2) INFORMATION FOR SEQ ID NO:66:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:	
ATATATTTA GTAAGCTTCA TCTTCT	26
(2) INFORMATION FOR SEQ ID NO:67:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:	
GACAAAGAAC GCGTGAAAAC TTT	23
(2) INFORMATION FOR SEQ ID NO:68:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 76 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68: CTGAACCTGT CTGGGACCAC AGTTGATGCT ATAGGATCAG ATCTAGAATT CATTTAGAGA	60
CTGGCCTGGC TTCTGC	76
(2) INFORMATION FOR SEQ ID NO:69:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 80 base pairs (B) TYPE: nucleic actid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:	
TCGACCGTTG GTAGGAATAA TGCAATTAAT GGAGTAGCTC TAAATTCAGA ATTCATCTAC	60
ACCCAGTGCA TCCAGTAGCT	80
(2) INFORMATION FOR SEQ ID NO:70:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

GGTAAACAGT AACGGTAAGA GTGCCAG

(2) INFORMATION FOR SEQ ID NO:71:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:	
CGCCTTCAGC CTAAGAAGCG TAGTCCGGAA CGTCGTACGG GTAGGATCCA CTAG	54
(2) INFORMATION FOR SEQ ID NO:72:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:72:	
CACCGGTTCG GGGAATTAGT CTTGACCAGG CAGCCCAGGG C	41
(2) INFORMATION FOR SEQ ID NO:73:	
(1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:	
ATTCCACACA TTATACGAGC CGGAAGCATA AAGTGTCAAG CCTGGGGTGC C	51
(2) INFORMATION FOR SEQ ID NO:74:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:	
CTGCTCATCA GATGGCGGGA AGAGCTCGGC CATGGCTGGT TG	42
(2) INFORMATION FOR SEQ ID NO:75:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

WO 92/06204

78

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:
GAACAGAGTG ACCGAGGGGG CGAGCTCGGC CATGGCTGGT TG

I Claim:

- 1. A composition of matter comprising a plurality of cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form heteromeric receptors, one or both of said polypeptides being expressed as fusion proteins on the surface of a cell.
 - 2. The composition of claim 1, wherein said plurality of cells are <u>E. coli</u>.
 - 3. The composition of claim 1, wherein said heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
 - 4. The composition of claim 1, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
 - 5. The composition of claim 4, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
 - 6. The composition of claim 1, wherein said cell produces filamentous bacteriophage.
 - 7. The composition of claim 6, wherein said filamentous bacteriophage are selected from the group consisting of M13, fd and fl.
 - 8. The composition of claim 6, wherein at least one of the encoded first or second polypeptides is expressed as a fusion protein with gene VIII.

- 9. A kit for the preparation of vectors useful for the coexpression of two or more DNA sequences encoding polypeptides which form heteromeric receptors comprising two vectors, a first vector having two pairs of restriction sites symmetrically oriented about a cloning site which can be combined with a second vector, having two pairs of restriction sites symmetrically oriented about a cloning site and in an identical orientation to that of the first vector, wherein one or both vectors contains sequences necessary for expression of polypeptides encoded by DNA sequences inserted in said cloning sites.
 - 10. The kit of claim 9, wherein said first and second vectors are circular.
 - 11. The kit of claim 9, wherein said expression peptides is as fusion proteins on the surface of a cell.
 - 12. The kit of claim 9, wherein said cell produces filamentous bacteriophage.
 - 13. The kit of claim 9, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.
 - 14. The kit of claim 13, wherein at least one of the DNA sequences is expressed as a fusion protein with gene VIII.
 - 15. The kit of claim 9, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

- or more DNA sequences encoding polypeptides which form a heteromeric receptor, comprising a set of first vectors having a diverse population of first DNA sequences and a set of second vectors having a diverse population second DNA sequences, said first and second vectors having two pairs of restriction sites symmetrically oriented about a cloning site for containing said first and second populations of DNA sequences so as to allow only the operational combination of vector sequences containing said first and second DNA sequences.
 - 17. The cloning system of claim 16, wherein said first and second vectors are circular.
 - 18. The cloning system of claim 16, wherein said heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
 - 19. The cloning system of claim 16, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
 - 20. The cloning system of claim 19, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
 - 21. The cloning system of claim 16, wherein said coexpression of two or more DNA sequences encoding polypeptides which form a heteromeric receptor is on the surface of cell.
 - 22. The cloning system of claim 16, wherein said cell produces a filamentous bacteriophage.

- 23. The cloning system of claim 22 wherein said filamentous bacteriophage selected from the group consisting of M13, fd and fl.
- 24. The cloning system of claim 23, wherein at least one of the DNA sequences is expressed as a fusion protein with the protein product of gene VIII.
- 25. The cloning system of claim 16, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.
- 26. A plurality of expression vectors containing a plurality of possible first and second DNA sequences encoding polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said DNA sequence encoding heteromeric receptors being operatively linked to genes encoding surface proteins of a cell.
 - 27. The expression vectors of claim 26, wherein said expression vectors are circular.
 - 28. The expression vectors of claim 23, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
 - 29. The expression vectors of claim 26, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
 - 30. The expression vectors of claim 29, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.

PCT/US91/07149

- 31. The expression vectors of claim 26, wherein said cells produce filamentous bacteriophage.
- 32. The expression vectors of claim 26, wherein said filamentous bacteriophage are selected from the group consisting of M13, fd and fl.
- 33. The expression vectors of claim 32, wherein at least one of the encoded first or second polypeptides is expressed as a fusion protein with gene VIII.
- 34. A method of constructing a diverse population of vectors capable of expressing a diverse population of heteromeric receptors, comprising:
 - (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;
 - (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector; and
 - (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.

5

10

15

- 35. The method of claim 34, wherein said first and second vectors are circular.
- 36. The method of claim 34, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 37. The method of claim 34, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 38. The method of claim 34, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell.
- 39. The method of claim 37, wherein said cell produces a bacteriophage.
- 40. The method of claim 39, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.
- 41. The method of claim 34, wherein at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.
- 42. The method of claim 34, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

WO 92/06204

5

- 43. The method of claim 34, wherein said combining step further comprises:
 - (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
 - (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
 - (C3) digesting the 3' ends of said
 restricted first and second vectors
 with an exonuclease; and
- 15 (C4) annealing said first and second vectors.

WO 92/06204

5

10

15

20

25

- 44. method Α for selecting a heteromeric receptor exhibiting binding activity toward a preselected molecule from a population of diverse heteromeric receptors, comprising:
 - (a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;
 - (b) operationally linking to a second vector a second population of diverse DNA sequences encoding a population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector:
 - (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.
 - (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences; and
 - (e) determining the heteromeric receptors which bind to said preselected molecule.

WO 92/06204 PCT/US91/07149

- 45. The method of claim 44, wherein said first and second vectors are circular.
- 46. The method of claim 44, wherein said heteromeric receptors are selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 47. The method of claim 44, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
- 48. The method of claim 47, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 49. The method of claim 44, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell.
- 50. The method of claim 49, wherein said cell produces a filamentous bacteriophage.
- 51. The method of claim 50, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.
- 52. The method of claim 51, wherein at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.
- 53. The method of claim 44, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.

5

- 54. The method of claim 44, wherein said combining step further comprises:
 - (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
 - (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
 - (C3) digesting the 3' ends of said restricted first and second vectors with an exonuclease; and
- 15 (C4) annealing said first and second vectors.

PCT/US91/07149

55. A method for determining the nucleic acid sequences encoding a heteromeric receptor exhibiting binding activity toward a preselected molecule from a diverse population of heteromeric receptors, comprising:

5

(a) operationally linking to a first vector a first population of diverse DNA sequences encoding a diverse population of first polypeptides, said first vector having two pairs of restriction sites symmetrically oriented about a cloning site;

10

(b) operationally linking to a second vector a second population of diverse DNA sequences encoding a diverse population of second polypeptides, said second vector having two pairs of restriction sites symmetrically oriented about a cloning site in an identical orientation to that of the first vector;

15

20

25

- (c) combining the vector products of step (a) and (b) under conditions which allow only the operational combination of vector sequences containing said first and second DNA sequences.
- (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of first and second DNA sequences;

WO 92/06204 PCT/US91/07149

5

90

(e) determining the heteromeric receptors which bind to said preselected molecule;

(f) isolating the nucleic acid sequences encoding said first and second polypeptides; and

- (g) sequencing said nucleic acid sequences.
- 56. The method of claim 55, wherein said first and second vectors are circular.
- 57. The method of claim 55, wherein said first heteromeric receptors selected from the group consisting of antibodies, T cell receptors, integrins, hormone receptors and transmitter receptors.
- 58. The method of claim 55, wherein said first and second DNA sequences encode functional portions of heteromeric receptors.
- 59. The method of claim 58, wherein said first and second DNA sequences encode functional portions of the variable heavy and variable light chains of an antibody.
- 60. The method of claim 55, wherein said expression of a diverse population of heteromeric receptors is on the surface of a cell filamentous bacteriophage selected from the group consisting of M13, fd and fl and at least one of said first or second DNA sequences is expressed as a gene VIII fusion protein.
- 61. The method of claim 55, wherein said cell produces filamentous bacteriophage.

WO 92/06204 PCT/US91/07149

91

62. The method of claim 61, wherein said filamentous bacteriophage is selected from the group consisting of M13, fd and fl.


- 63. The method of claim 62, wherein at least one of said frist or second DNA sequences is expressed as a gene VIII fusion protein.
- 64. The method of claim 50, wherein said two pairs of restriction sites are Hind III-Mlu I and Hind III-Mlu I.
- 65. The method of claim 50, wherein said combining step further comprises:
 - (C1) restricting said first vector with a restriction enzyme recognizing one of the restriction sites encoded in said two pairs of restriction sites;
 - (C2) restricting said second vector with a different restriction enzyme recognizing the second restriction site encoded in said two pairs of restriction sites;
 - (C3) digesting the 3' ends of said
 restricted first and second vectors
 with an exonuclease; and
 - (C4) annealing said first and second
 vectors.

5

10

- 66. A vector comprising two copies of a gene encoding a filamentous bacteriophage coat protein, one copy of said gene capable of being operationally linked to a DNA sequence encoding a polypeptide of a heteromeric receptor wherein said DNA sequence can be expressed as a fusion protein on the surface of said filamentous bacteriophage or as a soluble polypeptide.
 - 67. The vector of claim 66, wherein said two copies of said gene encode substantially the same amino acid sequence but have different nucleotide sequences.
 - 68. The vector of claim 66, wherein said one copy of said gene is expressed on the surface of said filamentous bacteriophage.
 - 69. The vector of claim 66, wherein said bacteriophage coat protein is M13 gene VIII.
 - 70. The vector of claim 66, wherein said vector has substantially the same sequence as that shown in Figure 2 (SEQ ID NO: 1).
- 71. A vector comprising sequences necessary for the coexpression of two or more inserted DNA sequences encoding polypeptides which form heteromeric receptors and two copies of a gene encoding a filamentous bacteriophage coat protein, one copy of said gene capable of being operationally linked to one of said two or more inserted DNA sequences wherein said DNA sequence can be expressed as a fusion protein on the surface of said filamentous bacteriophage or as a soluble polypeptide.
 - 72. The vector of claim 71, wherein said two copies of said gene encode substantially the same amino acid sequence but have different nucleotide sequences.

- 73. The vector of claim 71, wherein said one copy of said gene is expressed on the surface of said filamentous bacteriophage.
- 74. The vector of claim 71, wherein said bacteriophage coat protein is M13 gene VIII.
- 75. The vector of claim 71, wherein said vector has substantially the same sequence as that shown in Figure 6 (SEQ ID NO: 5).



2/11

1 10 1 1 10 1 1 10 1 1 10 1 1 10 1 1 10 1 10 1 10 10	TGA CCATTTGCGA AATGTATC ATC AACTGTTACA TGGAATGA TGT TGAGCTACAG CACCAGAT TTA TCAAAAAGGAG CAATTAAA TCT GGTTCGCTTT GAAGCTCG TAA TCTTTTTTGAT GCAATCCG TAA TCTTTTTTGAT GCAATCCG TTT TGATTTATGA ACTTCTTC GAA TATTTATGAC GATTCCTC GAA TATTTATGAC GATTCCTC GAA TATTTATGAC GATTCCTC TGAA TAATGTTGTT CCGTTAGT TCAATGATTGTT CCGTTAGT TCAATGTTGTT CCGTTAGT TCACTGAATG AGCAGCTC TTT AAACCATCTC AAGCAGGTC TTT AAACCATCTC TGAAGCTCCT TCACTGAAACTT TGTTTCGCA ACC TCTTTCAAAG TTGATTCCCT TCATTCTTTCG CCAACCTTT TCACTCCTCGT TCCGAAGCTC TTG TCATTCTTCG CAACCTCT TCATTGTAAAACTT TTAGATCGT ACC CGTTTAAATGT ACTGGTGAC GC TGTTGAAAACTT TTAGATCGT GC TGATCCCTCGAA AATGAGGGT CT TCATTGTCGGT ACTAAACCT TCT TCACTCTCTC GACGGCACTT ACC CGACAAAACT TTAGATCGT GC TGTTGAAAACT TTAGATCGT GC TTACCCTTGAA AATGAGGGT ACC TTACCCTTGAA AATGAGGGT ACC TTACCCTTGAAACCT TTAGATTGTT ACTTGATCACT CT TTACCCTTGAAACCT TTAGATCTCTCAG GC TTACCCTTCAG GC TTACCCCTCAG GC TTACCCTTCAG GC TTACCCTTCAG GC TTACCCCTCAG GC TTACCCCCTCAG GC TTACCCCCCAG GC TTACCCCCCCAG GC TTACCCCCCCAG GC TTACCCCCCCAG GC TTACCCCCC	TA ATGGTCAAAC TAAATCTACT 120 AA CTTCCAGACA CCGTACTTTA 180 TC AGCAATTAAG CTCTAAGCCA 240 GG TACTCTCTAA TCCTGACCTG 300 AA TTAAAACGCG ATATTTGAAG 360 CT TTGCTTCTGA CTATAATAGT 420 GT TTTCTGAACT GTTTAAAGCA 480 AG TATTGGACGC TATCCAGTCT 540 TG CAAAAGCCTC TCGCTATTTT 600 TG TTGCTCTTAC TATGCCTCGT 660 TG GTATTCCTAA ATCTCAACTG 720 TC GTTTTATTAA CGTAGATTTT 780 TA AAATCGCATA AGGTAATTCA 840 TT TACCACTCGT TCTGGTGTTT 900 TG TTACGTTGAT TTGGGTAATG 960 CT CGGTTCCCTT ATGATTGACC 1020 TT CGGTTCCCTT ATGATTGACC 1020 TT CGGTTCCCTT TCTGGTGTA 1240 TC GGTATCAAGT CTTTAGTCCT 1320 TA AACCCCATAC AGAAAATTCA 1680 TC ATGAAAAAGT CTTTAGTCCT 1320 TA ACCCCATAC AGAAAATTCA 1680 TA CGGTTCCTTTT GGAGCCTTTT 1560 A AACCCCATAC AGAAAATTCA 1680 TC ATGAAAAAAGT CTTTAAGAA 1500 A TTCCTTTAGT TGTTCCTTTC 1620 A AACCCCATAC AGAAAATTCA 1880 TC ACGCTACCGTG TTACCGGTACA 1800 TC ACGCTACCG TGATACACCT 1920 TACCGCCTGG TACTGAGCAA 1980 C CTGAGTACGG TACTGAGCAA 1980 C CTCTTAATAC TTTCATGTTT 2040
2221 GATCCATTCG TTTGTGAA 2281 GCTGGCGGCG GCTCTGGT 2341 GGCGGTTCTG AGGGTGGC 2401 GATTTTGATT ATGAAAAG 2461 GAAAACGCGC TACAGTCTC 2521 GCTGCTATCG ATGGTTTC 2581 GGTGATTTTG CTGGCTCT 2641 TTAATGAATA ATTTCCGTC 2701 TTTGTCTTTA GCGCTGGT 2701 TTTGTCTTTA GCGCTGGT 2701 TTTGTCTTTA GCGCTGGT 2821 TTTGCTAACA TACTGCGTA 2821 TTTGCTAACA TACTGCGTA 3001 GGCTTAACTC AATTCTTGT 3001 GGCTTAACTC AATTCTTGT 3121 TCTCTGTAAA GGCTGCTAT 3121 TCTCTGTAAA GGCTGCTAT 3121 TCTCTGTAAA GGCTTCAGAT 3301 CTTGATTTAA GGCTTCAAA 3301 CTTGATTTAA GGCTTCAAA 3301 CTTGATTTAA GGCTTCAAA 3361 TTGTCGGTA TAGGCTGAAC 3421 TCCTACGATG AAAATAAAA 3541 AAATTAGGAT GGGATATTA 3601 CGTTCTGCAT TAGCTGAAC 3661 TTTGTCGGTA CTTTATATT 3721 GTTGGCGTTG TTAAATATG	GG TGGTTCTGGT GGCGGCTCTGGG CTCTGGG CTCTGGGG CTCTGGG CTCTGGT GGCGGTTCCGT GGCGGCTCTGAT GGCGGCCTCGAA CGCCAAACGGC AAACTTGATGAA TTCCCAAATGAA TTCCCAAATGAA TTTCCATTGAA ACCATATGAA TTTCCATTGAA ACCATATGAA TTTCCATTGAA TTCCTTCTTGAT TAATCATGCGAAATGAA TTTCATTTGATTTG	G AGGGTGGTGG CTCTGAGGGT 2340 G GTGGTGGCTC TGGTTCCGGT 2400 G CTATGACCGA AAATGCCGAT 2460 T CTGTCGCTAC TGATTACGGT 2520 G CTAATGGTAA TGGTGCTACT 2580 G GTGACGGTGA TAATTCACCT 2640 C AATCGGTTGA ATGTCGCCCT 2700 G ATTGTGACAA AATAAACTTA 2760 T TTATGTATGT ATTTTCTACG 2820 C AGTTCTTTTG GGTATTCCGT 2880 T CGGCTATCTG CTTACTTTTC 2940 T GTTTCTTGCT CTTATTATTG 3000 G CGCTCAATTA CCCTCTGACT 3060 T CCCTGTTTT TATGTTATTC 3120 A AAAAATCGTT TCTTATTATTG 3180 A AATTAGGCTC TGGAAAGACG 3240 G GGTGCAAAAC GCCTCGCGTT 3360 T TCGCTAAAAC GCCTCGCGTT 3360 C CTATTGGTTCT ACATGCTCGT 3540 C CTATTGGTTTCT ACATGCTCGT 3540 T TGGCTAGAAAT TACATTACCT 3660 TGCCTCTGCC TAAATTACAT 3720

63361 63361 63361 63361 63421 6566666 6567 701401 772321 7723381	TCCGGTGTTTAACACCTTCAACACTTCAACACCCTCAACACCCCAACACCCCAACACCCCAACACCCCAACACCCC	ATTACATTACACTACACTACTACACTACACTACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACACTACACACTACACACTACACACTACACACTACACACTACACACTACACACACTACACACACTAC	T AACGCCTTA A GCTTACTAA C ATCAGCATT TCAGACCTA TCAGATTATTCA A AGGTTATTCA CTCAGGTAA CTGATATGATA CTGATATGATA	TTATCACAC A ATATATTATCACAC A ATATATTATTAT T ACATATATATAT T GATTTTGAT T TTCAAGGAT T TTCAAGGAT T TAGATATATAT T TAGATATATAT T AAATGTAAT T AACCTGAAAT T ATCTCAAGTT T ATCTCAAGTT T ATCTCAAGTT T ATCTCAAGTT T TCAAGTTCCT T ATCTCAAGTT T TCAAGTTCCT T ATCTCAAGTT T CACTCTGTT T CACTCTGT T CACTCTG T CACTCG T CACTCTG T CACTCG T CACTCTG T CACTC	G GTCGGTATT A AAAAGTTTT T ATATAACCC A AATTCACTA T CTAAGGGAA A TTGATTTATT T AATTTCGCT T CTACGCAAT T CTTGATAAT T CTTGATTAAT T CTTGATAAT T CT	TO A TO A CONTRACT TO A CONTRA	3900 3960 4020 4020 4140 4260 4260 4260 4380 44500 45620 4740 4860 4860
---	---	---	---	--	--	--	--

5 / 11

```
3841 TCCGGTGTTT ATTCTTATTT AACGCCTTAT TTATCACACG GTCGGTATTT CAAACCATTA 3900
3901 AATTTAGGTC AGAAGATGAA GCTTACTAAA ATATATTTGA AAAAAGTTTTC ACGCGTTCTT 3960
3961 TGTCTTGCGA TTGGATTTGC ATCAGCATTT ACATATAGTT ATATAACCCA ACCTAAGCCG 4020
4021 GAGGTTAAAA AGGTAGTCTC TCAGACCTAT GATTTTGATA AATTCACTAT TGACTCTTCT 4080
4081 CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGGATT CTAAGGGGAAA ATTAATTAAT 4140
4141 AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TACTGTTTCC 4200
4201 ATTAAAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGTTT TCTTGATGTT 4260
4261 TGTTTCATCA TCTTCTTTTG CTCAGGGTAAT TGAAATGAAT AATTCGCCTC TGCGCGATTT 4320
4381 TACTGTTACT GTATATTCAT CTGACGTTAA ACCTGAAAAAT CTTTCCCCG ATGTAAAAAGG 4380
4381 TACTGTTACT GCTAATAATT TTGACGTTGAT TGTTTCCATAA TCCAGAAGTA 4500
4561 TGATAATTCC GCTCATTCTG GTGGTTTCTT TGTTCCGCAA AATGACATG TTACTCAAAAC 4620
4561 TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATT TGTTTTGTAAA 4680
4561 TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATT TGTTTTGTAAA 4680
4681 GTCTAATACT TCTAAAACCT CAAATGTATT ATCTATTGAC GGCTCTAAATC TATTAGTTGT 4740
4741 TAGTGCACCT AAAGATATT TAGATAACCT TCCTCCAATC CTTTCTAATC TATTAGTTGT 4740
4741 TAGTGCACCT AAAGATATT TAGATAACCT TCCTCCAATC CTTTCTAATC TATTAGTTGC 4800
4801 AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGTT ATCTAATC CAAATGTTT ATCTAATCC GCGATGTTTAATC AGGAATATTT TAGATAGCT CTTTCTAATC CAAATGTTT ATCTAATACGA GTTTTTAATC CACATGTTT ATCTAATACGA 4860
4861 GTCTAATTT GCTGCTGCT CTCAGCGTGG CACTGTTGCA GTTTTTAATA CACATGTTT ATCTAATC
                       4861
      4921
4981
      5041
       5101
    5161
   5221
5281
5341
     5401
   5461
5521
5581
    5641
  5701
5761
5821
  5881
  5941
  6001
6061
6121
6181
 6241
6301
 6361
6421
6481
6541
6601
6661
6721
6781
6841
6901
6961
7021
7081
7141
7201
```

FIG. 3-2

AATGCTACTA ATAGCTAAAC CGTTCGCAGA GTTGCATATT TCTGCAAAAA TTGGAGTTTG TCTTTCGGGC CAGGGTAAAG 301 481 TTTGAGGGGG ATTCAATGAA
541 AAACATTTTA CTATTACCCC
601 GGTTTTTATC GTCGTCTGGT
661 AATTCCTTTT GGCGTTATGT
721 ATGAATCTTT CTACCTGTAA
781 TCTTCCCAAC GTCCTGACTG 780 1021 1081 CACAATTTA I CGCTGGGGGT TGCCTTCGTA CTTTAGTCCT CTGAGGGTGA ATATCGGTTA TGTTTAAGAA GGAGCCTTTT TGTTCCTTTC AGAAAATTCA TGAGGGTTGT TTACGGTACA GGGTGGCGGT TGATACACCT 1261 1321 1320 Ī501 1620 1621 TGATACACCT TACTGAGCAA 1981 TTTCATGTTT 2101 2161 2221 2281 2341 CACTGTTACT AAAAGCCATG AAAAGCCATG 2160 CTTTAATGAA 2220 TCCTGTCAAT 2280 CTCTGAGGGT 2340 TGGTTCCGGT 2400 AAATGCCGAT 2460 TGATTACGGT 2520 TGGTGCTACT 2580 TAATTCACCT 2640 ATGTCGCCCT 2700 AATAAACTTA 2760 ATTTTCTACG 2820 2521 2581 2641 2701 2761 2821 2881 2941 GCGCTGGTAA TCTTTGCGTAA TCTTCCTCGGTAAG TTTCCTCGGTAAG AATTCTTGTG TGTTCAGTTA GGCTGCTATT ATAATATGGC TTGGTAAGAT GGCATAAGAA CGGATAAGAA GGAATAATAA GGGATATAT TAGCTGAACA CTTTATATTC TTAAATATGG ATTTGTATAA AATAAACTTA 2760
ATTTTCTACG 2820
GGTATTCCGT 2880
CTTACTTTTC 2940
CCTTACTTTTC 3060
TATGTTATTC 3120
TCTTATTTTGG 3180
TGGAAAGACG 3240
AGCAACTAAT 3300
CGGTAATGAT 3420
TTGGTTTAAT 3480
ACATGCTCGT 3540
TAAACAGGCG 3600
TACTTTACCT 3660
TACTTTACCT 3660
TAAATTACAT 3720 TATTATTGCG
TTAAAAAGGG
GGCTTAACTC
TTGTTCAGGG
TCTCTGTAAA
ATTGGGATAA
CTCGTTAGCG
CTTGATTTAA
CTTAGAATAC
TCCTACGATG
ACCCGTTCTT
AAATTAGGAT
CGTTCTGCAT
TTTGTCGGTA
GTTGGCGTTG
ACTGGCGTAG 300ī 3181 3241 3301 3541 TTTTCTTGTT TGTTGTTTAT TCTTATTACT TGTCGTCGTC TGGACAGAAT 3721 3781 TTTGTCGGTA CTTTATATTC TCTTATTACT GGCTCGAAAA TGCCTCTGCC TAAATTACAT 3720 GTTGGCGTTG TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT 3780 ACTGGTAAGA ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTTCTAG TAATTATGAT 3840

7/11

]

3334444444444444444444444445555555555666666	GTAGAGATTAAAAGAAGAACCAATTAACGAAAAAAAAAA	GAGCTTATTAGAGGGCTCAGAGGCTCAGAGGCTTAGAGGCTTAGAGGTTAGAGGGGGGGG	TTTAGATACTAGATTCTTTTTTTTTTTTTTTTTTTTTTT	TGAAAAGCACAAATTTAAACAATTTAAAATTCGCAAAATTTAAAATTCGCAAAAAATTTAAAATTCGCAAAAAAAA	TTCACGACACACACACACACACACACACACACACACACAC	CTGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	34444444444444444444455555555555566666666
7201 7261	ACCCTCTCCG ACTGTCTCCG TTTAAAATAT	GACTCTCAGG GCATTAATTT GCCTTTCTCA ATGAGGGTTC TACAGGGTCA	CAATGACCTG ATCAGCTAGA CCCTTTTGAA TAAAAATTTT TAATGTTTTT	ATAGCCTTTG ACGGTTGAAT TCTTTACCTA TATCCTTGCG	TAGATCICTC ATCATATTGA CACATTACTC TTGAAATAAA ATTTAGCTTT	AAAAATAGCT TGGTGATTTG AGGCATTGCA GGCTTCTCCC ATGCTCTGAG	7260 7320

FIG. 5-2

```
1 1 / 1 1
4081 CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT 4140
4141 AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TACTGTTTCC 4200
4201 ATTAAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGGTT TCTCGATGTT 4260
```

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US91/07149

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate ail) 6 According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12N 15/64, 15/70U.S.C1.: 435/252.3, 320.1 II FIELDS SEARCHED Minimum Documentation Searched ? Classification System Classification Sympols 435/69.7, 172.3, 252.3, 320.1 U.S.C1. Documentation Searched othe "han Minimum Documentation to the Extent that such Document, are Included in the Fields Searched 8 APS, STN/MEDLINE, TERMS USED: SURFACE EXPRESSION VECTOR#, DIRECTED EVOLUTION, SINGLE CHAIN ANTIBOD?. III. DOCUMENTS CONSIDERED TO BE RELEVANT 9 Citation of Document, 11 with indication, where appropriate, of the relevant passages 12 Category * Relevant to Claim No. 13 Y 70.A, 89/36880 (FOM ET AL) 07 September 1988 see entire document. Muclair Acada Research, Vol. 12, No. 9, Υ 5-75 accused TEFTIMBER 1984, BCSS ET AL, "Assembly of functional antibodies from immunoglobulin heavy and light chains synthesized in E. coli", pages 3731-3806, see the abstract. Y Proceedings of the National Academy of 1 - 75Sciences, Vol. 35, issued AUGUST 1989, SASTRY Et AL, "Cloning of the immunological repertoire in Cocharichia gali for generation of monoclonal satalytic antibodies: Construction of a heavy chain variable-region specific cDNA library*, pages 5728-5702, see the abstract. Science, Vol 246, issued 08 December 1989, Huse et al, Y "Generation of a Large Combinatorial Library of the 1-75 Immunoglobulin Repertoire in Phage Lambda", pages 1275-1281, see entire document. Special categories of cited documents: 10 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed in the art. "&" document member of the same patent family IV. CERTIFICATION Date of the Actual Completion of the International Search Date of Mailing of this International Search Report **21** JAN 1992 06 January 1992 International Searching Authority Signature of Authorized Officer ISA/US John D. Ulm

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET	16176391707149
	1.
Y Dene, Vol. 70, issued 1988, PARMLEY ET AL, "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes", pages 205-218, see entire document	
V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE	
This international search report has not been established in respect of certain claims under Article	17(2) (a) for the following reasons:
1. Claim numbers . because they relate to subject matter 12 not required to be searched	by this Authority, namely:
Claim numbers because they relate to parts of the international application that do no ments to such an extent that no meaningful international search can be carried out ¹³ , specific	t comply with the prescribed require-
	any:
į.	
3. Claim numbers because they are dependent claims not drafted in accordance with the PCT Rule 6.4(a).	second and third sentences of
VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING 2	
This International Searching Authority found multiple inventions in this international application as to	oliows:
 As all required additional search fees were timely paid by the applicant, this international search of the international application. 	report covers all searchable claims
2. As only some of the required additional search fees were timely paid by the applicant, this intentional application for which fees were paid, specifically claims:	rnational search report covers only
3. No required additional search fees were timely paid by the applicant. Consequently, this internate the invention first mentioned in the claims; it is covered by claim numbers:	tional search report is restricted to
As all searchable claims could be searched without effort justifying an additional fee, the interning invite payment of any additional fee.	ational Searching Authority did not
Remark on Protest	
The additional search fees were accompanied by applicant's protest. No protest accompanied the payment of additional search fees.	